

The predictive value of NTproBNP on postoperative outcome in patients undergoing offpump CABG

Ibrahim AbuBakr ElSeddiq

September 16, 2020

1 Review of Literature

1.1 Physiology of Natriuretic Peptides

History

The history of the NP class of biomarkers dates back to 1950s when early electron microscopy studies reported dense granules in the atrial myocardium similar to glandular tissue from endocrine organs. Soon, the close interplay between atria and intravascular volume was revealed; stretching of canine left atrium increased urine output and injection of atrial tissue into rats caused diuresis and natriuresis. Atrial natriuretic peptide (ANP) was subsequently purified, sequenced, and reproduced. [Gaggin and Januzzi, 2014]

B-Type natriuretic peptide was discovered in 1988. Proof of the existence of amino-terminal pro-B-type natriuretic peptide (NTproBNP) in the human circulation and its relationship to cardiac function were first reported by Hunt and colleagues in 1995. [Richards, 2018]

Although BNP was first isolated from the brain, that it is predominantly expressed in the ventricle. ANP and BNP were therefore renamed A-type and B-type natriuretic peptide, respectively, to better reflect their position in the family and to also lessen the misleading nature of the nomenclature of BNP as a cardiovascular and not a neural factor. ANP and BNP are the natriuretic peptides which are expressed predominantly in the atria and ventricle, respectively, and are referred to as the cardiac natriuretic peptides. [Suzuki et al., 2001]

Other NPs that share a common biochemical structural feature, a 17-amino-acid ring and a disulfide bridge between cysteine molecules, have been discovered since: urodilantin (an isoform of ANP), C-type natriuretic peptide, and Dendroaspis natriuretic peptide. [Gaggin and

Januzzi, 2014]

CNP is differentially expressed mainly in the nervous system and vasculature (e.g. endothelial cells, monocyte / macrophages) and is involved mainly in neural regulation as well as vascular control although its role is unclear. [Suzuki et al., 2001]

Structure and release

Each natriuretic peptide is coded by a separate gene. In humans, the ANP and BNP genes are located 8 kilobases apart on chromosome 1 and the CNP gene is located on chromosome 2. Each natriuretic peptide gene produces a prohormone or precursor protein. [Suzuki et al., 2001]

All NPs derive from pre-pro-hormones (i.e., preproANP and preproBNP), containing a signal peptide sequence at the amino-terminal end. The pro-hormones (i.e., proANP and proBNP) are produced by cleavage of signal peptide, and then are further split into inactive longer NH-2-terminal fragments (i.e., NT-proANP or NT proBNP), and a biologically active shorter COOH-terminal peptide (i.e., ANP or BNP), which are secreted in the blood in equimolar amounts. However, ANP and BNP have a shorter plasma half-life and consequently lower plasma concentration, compared to NT-proANP and NTproBNP [Clerico and Emdin, 2004]

ANP is encoded by the NPAA gene on chromosome 1. It is translated into a 151-amino-acid pre-prohormone (preproANP) that is cleaved in the sarcoplasmic reticulum to a 126-amino-acid prohormone (proANP), which is stored in intracellular granules. When stimulated and released, proANP is further cleaved into a 28-amino-acid bioactive form (ANP) and a 98-amino-acid N-terminal fragment (NT-proANP). The half-life of ANP is approximately 2 minutes, whereas NT-proANP half-life is variable depending on the fragment measured. [Volpe et al., 2016]

Transcription of the BNP gene first results in a 134-amino-acid intracellular pre-pro-peptide, which is rapidly processed to a 108-amino-acid precursor peptide, proBNP 1-108 . This peptide is cleaved into the biologically active 32-amino-acid BNP and a biologically inert 76-amino-acid, NTproBNP, before being released into circulation within minutes of their production. The degree of peripheral conversion of proBNP 1-108 is not known, but it is clear that a certain percentage of uncleaved pro-peptide is also released, particularly in those with more advanced HF. [Gaggin and Januzzi, 2014]

CNP produces 22 and 53 amino acid fragments. The 22 amino acid fragment is the mature and more active form, and is expressed in the nervous system and endothelial cells. The common property of the natriuretic peptides is the formation of a disulfide bond which results in a ringed structure.[Suzuki et al., 2001]

Processing of proCNP to its mature form may occur through the action of the intracellular serine endoprotease, furin. In vitro, furin cleaves the 103 amino acid proCNP into a 53 amino acid carboxyl-terminal biologically active peptide [Wu et al., 2003b]. This 53 amino acid form of CNP (CNP-53) is the major active form of CNP, at the tissue level. However, in the systemic circulation, a shorter 22 amino acid form dominates (CNP-22). The protease responsible for this cleavage is not known. Importantly, CNP-53 and CNP-22 appear to bind and activate their cognate receptor, NPR-B, equally well.

ANP is presynthesized and stored in granules before being released by a stimulus, whereas the B-type peptides' release into circulation is largely regulated at the level of the BNP gene expression. [Gaggin and Januzzi, 2014]

ANP is secreted in response to:

- Stretching of the atrial wall

- Reduced Sympathetic stimulation of β -adrenoceptors
- Raised sodium concentration (hyponatremia), though sodium concentration is not the direct stimulus for increased ANP secretion. [?]

The major stimulus for ANP release is increased atrial wall stretch reflecting increased intravascular volume. Other stimuli for release include catecholamines, arginine vasopressin, and endothelin. These stimuli reflect the counter-regulatory role ANP plays against volume overload and hypertension. [Maisel and Wettersten, 2018]

ANP's rapid response to changing hemodynamics is because it is pre-made and stored in the myocardium, which contrasts to the B-type peptides. However, the half-life of ANP is extremely short at 2 to 5 minutes, which makes its reliable detection difficult and dilutes its clinical value. Recently, a renewed focus has been placed on ANP as its immediate precursor protein, proANP, appears to have a longer half-life. A novel assay that detects the midregion of proANP (MR-proANP) has been developed and evaluated for its role in HF. [Gaggin and Januzzi, 2014]

BNP can be produced in both atria and ventricles, and is upregulated in failing ventricular myocardium. In response to increased myocardial stretch and wall stress, ventricular myocytes secrete the pro-hormone pre-proBNP, which is then cleaved into biologically active BNP and the inactive byproduct N-terminal-proBNP (NTproBNP). Elevated BNP levels have been demonstrated to be a response to increased angiotensin II and sympathetic tones. [Iwanaga et al., 2006]

Data suggest that the major part of proBNP produced in myocytes is apparently processed prior to release; however, intact proBNP peptide was also found in plasma of patients with HF as well as healthy adult subjects [Goetze, 2004a].

BNP and NTproBNP are secreted in equimolar quantites into the circulation. BNP has a serum half-life of 20 minutes, whereas NTproBNP has a half-life of 120 minutes. [Daniels and Maisel, 2007]

The BNP gene is strongly induced in response to myocardial stretch, predominantly from elevated left ventricular (LV) volume or pressures, and the stretch is thought to be the principal stimulus for BNP production. However, other processes also contribute to the activation of the BNP gene, such as inflammation, activation of the sympathetic nervous system, and the renin-angiotensin-aldosterone system as well as myocardial ischemia. Some suggest that there may be an alternative mechanism of rapid BNP release because BNP levels can increase faster than expected from the gene induction pathway in the setting of acute coronary syndrome (ACS), but the exact mechanism remains elusive. [Gaggin and Januzzi, 2014]

CNP is not stored in granules and its secretion is increased by growth factors and sheer stress in cultured endothelial cells. CNP expression in neo-intimal vascular smooth muscle cells is increased in response to vascular injury. In normal human subjects, mean CNP concentration is very low (1 fmol/ml). It is elevated in patients with congestive heart failure, although to a much lower extent than ANP and BNP [Charles et al., 2006]

Studies on structure-activity relationships have shown the importance for the binding to the specific receptors of the central ring structure of NPs, formed by a disulfide bridge between the two cysteine residues. For this reason, only ANP and BNP, which present the disulfide bridge in the peptide chain, share the typical hormonal activity of NPs, while the NT-proANP and NTproBNP do not [Clerico and Emdin, 2004] [Goetze, 2004b] [Clerico et al., 2002].

The circulating levels of NPs are regulated or modified by several physiological factors (such as circadian variations, age, gender, exercise, body posture, and water immersion), eating habits (especially sodium




Figure 1: CAPTION Structure of the human natriuretic peptides. The structure of the preprohormones for ANP, BNP and CNP are outlined on the left of each panel. The final amino acid sequence and structure of the mature peptides along with the major degradation product are shown on the right. The sites of cleavage are indicated with scissors.




Figure 2: CAPTION ANP and BNP physiology. (A) Molecular structure of ANP (top) and BNP (bottom) showing enzymatic cleavage sites and end-product fragments. (B) Production and processing of ANP by atrial cardiac myocyte in response to mechanical stretch stimulus. (C) Production and processing of BNP by ventricular cardiac myocyte in response to mechanical stimulus. (D) Effects of ANP and BNP on target tissues. Both ANP and BNP bind NP receptor (NPR)A and NPR-B on target cells, inducing cleavage of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) by cytoplasmic G proteins, initiating an intracellular cGMP signaling cascade involving protein kinase G (PKG), ultimately leading to downstream transcription of genes involving smooth muscle cell relaxation, diuresis and natriuresis (depending on target tissue). Both ANP and BNP are broken down in serum by circulating endogenous peptidases, including neprilysin. ANP and BNP are also degraded (to a lesser extent) by cellular uptake through binding NPR-C, undergoing receptor mediated endocytosis and intracellular breakdown by lysosomes. [Maisel and Wettersten, 2018]

intake), clinical conditions, and drugs (including corticosteroids, sex steroid hormones, thyroid hormones, diuretics, angiotensin-converting enzyme [ACE] inhibitors, and adrenergic agonists and antagonists) [Clerico and Emdin, 2004]

The increase in NPs with aging may be due to the decline in myocardial function and other organs (including kidney), typical of senescence. In this case, the NPs assay may be considered as a biochemical marker of increased risk of cardiac morbidity in old age [Ueda et al., 2003].

The increase in NPs with aging may also be due to a decrease in their clearance rate. Indeed, an age modulation of maximum binding capacity of clearance (C-type) receptors for NPs was reported in platelets of elderly persons [Giannessi et al., 2001].

The possible influence of sex steroid hormones on the NPs system, as well as the modification of the cardiovascular system with aging, should be taken into account. According to these mechanisms, the higher NPs values of women during the fertile adult period could be explained by the physiological stimulation of female sex steroid hormones. In particular, the BNP concentration is on average 36% higher in women than in men aged less than 50 years [Clerico et al., 2002].

Studies showed that both BNP and NTproBNP levels are influenced by biological variation, with the biological variation of BNP being higher compared to NTproBNP (up to 44% and up to 35% respectively). [Bruins et al., 2004]

Absolute values of BNP are significantly lower than values of NTproBNP, despite equimolar secretion. The reference ranges for BNP and NTproBNP vary depending on the assay that is used and the nature of the control population. In general, the suggested normal range for circulating BNP is 0.5-30 pg/ml and for circulating NTproBNP the suggested normal range is 68-112 pg/ml. [Cowie et al., 2003]




Figure 3: CAPTION Secretion of BNP and NTproBNP




Figure 4: CAPTION The causes and mechanisms of elevated natriuretic peptides levels.

Elevated natriuretic peptides levels can be found in many circumstances involving LV dysfunction or hypertrophy; right ventricular (RV) dysfunction secondary to pulmonary diseases; cardiac inflammatory or infectious diseases; and endocrinologic diseases and high output status without decreased left ventricular ejection fraction (EF), e.g., sepsis, renal failure, cirrhosis of liver, or intracranial pathologies. The causes and mechanisms of elevated natriuretic peptides levels are summarized in Fig. 4.

In the circulation, NPs are metabolized via two principal mechanisms: degradation by a membrane-bound endopeptidase (NEP 24.11) and receptor-mediated cellular uptake via NPR-C [Goetze, 2004a].

BNP is eliminated by binding to the NPR-C or degradation by NEP on endothelial cells, smooth muscle cells, cardiac myocytes, renal epithelium, and fibroblasts. NTproBNP is cleared mainly by the kidney. Compared to ANP, circulating BNP has a significantly longer half-life of around 20 min in humans; the half-life of NTproBNP is about 60-90 minutes and would be expected to be longer in the setting of renal dysfunction. [Pankow et al., 2007]

Unlike ANP, BNP is not initially cleaved by NEP. Instead, the first six amino-terminal amino acids of BNP are first cleaved by the metalloprotease, meprin A in the kidney brush border, which then allows further degradation by NEP. [Pankow et al., 2007]

While NEP enzymes are mainly involved in natriuretic peptide inactivation in vivo, the degradation of BNP seen in vitro is most likely due to other enzymes, such as peptyl arginine aldehyde proteases, kallikrein, and serine proteases [Belenky et al., 2004].

Obese patients tend to have lower BNP levels than others. Neural endopeptidases that can be secreted by adipose tissue may be related to increased BNP clearance in obese patients. [?]

Biochemical properties of prominent NP				
	Size (kDa)	Half-Life (min)	Normal Ranges Male (pg/mL)	Normal Ranges Female (pg/mL)
BNP	3.5	21	8.0	13.9
NT- proBNP	8.5	60–120	46.9	64.3

Figure 5: CAPTION a) Intra-individual, day-to-day biologic variation in patients with established HF. [Gaggin and Januzzi, 2014]

A very small amount of immunoreactive BNP has been found in urine, but the precise mechanism of renal excretion has not yet been fully clarified. [Ng et al., 2004]

NTproBNP is accepted to be more biochemically stable than BNP. BNP, when left at room temperature or when without a protease inhibitor such as ethylenediaminetetraacetic acid (EDTA) added, is prone to degradation, with rapid loss of immunoreactive peptide. BNP should be drawn into plastic rather than glass tubes because of degradation. NTproBNP, on the other hand, is much more flexible; it can be drawn into glass or plastic tubes and does not require an addition of protease inhibitors such as EDTA. NTproBNP can be drawn into serum, heparin plasma, or EDTA. The intra-individual, day-to-day biologic variation in stable HF patients is about 38% for BNP and 28% for NTproBNP; in patients without HF, these figures are considerably larger, but it is worth noting that substantially higher biologic variation in patients with extremely low concentrations is rarely of clinical importance. [Gaggin and Januzzi, 2014]

BNP is removed from circulation by both receptor-mediated mecha-

nisms (NPR type C) and enzymatic processes (neutral endopeptidases, meprin-A, and dipeptidylpeptidase IV present in various tissues). On the other hand, NTproBNP is passively cleared by multiple organs with high blood flows, including the kidneys. About a quarter of both BNP and NTproBNP are cleared by renal mechanisms, down to an estimated glomerular filtration rate of less than 15 mL/min/1.73 m². Because of the above-mentioned differences in the mechanism of clearance, the circulating half-life of BNP is much shorter at about 20 minutes, whereas that for NTproBNP is longer at about 70 minutes. [Gaggin and Januzzi, 2014]

The assay of the inactive propeptides better fits the definition of disease marker than the assay of circulating levels of ANP or BNP, which, on the other hand, may be considered a more reliable index of the activation status of the NPs system. Considering the biochemical and physiological characteristics of the different peptides, it is conceivable that ANP is a better marker of acute overload and/or rapid cardiovascular hemodynamic changes than BNP and, especially, than NT-proANP or NTproBNP [Clerico and Emdin, 2004]

Theoretically, setting up an immunoassay for NT-proANP and NTproBNP should be easier because their plasma concentrations are higher than ANP and BNP. On the other hand, NT-proANP and NTproBNP immunoassays may be affected by several analytical problems, mainly concerning the different assay specificities; consequently, very different results are produced by different methods with a large bias. The different analytical performance might affect the diagnostic accuracy of the assays, in discriminating between subjects with or without cardiac disease [Clerico and Emdin, 2004]

Most of the commercially available assays for BNP and NTproBNP are sandwich immunoassays, which considerably improved the specificity as well as sensitivity of enzyme-linked immunosorbent assays. Although there is no cross-reactivity between BNP and NTproBNP assays, recent evidence suggests that a substantial percentage of what

is detected as "BNP" or "NTproBNP" by available immunoassays for each may in fact be a mixture of the targeted protein as well as (as noted above) uncleaved proBNP 1-108 ; in the case of BNP, various degraded fragments are also detected. 18 The mechanism explaining the release of proBNP 1-108 is not known, but studies have shown that circulating proBNP 1-108 concentrations are elevated in patients with more advanced HF. Importantly, proBNP 1-108 has reduced or absent biologic activity relative to BNP; the lack of a diuretic and natriuretic effect is clearly deleterious to the patient with HF and implies a potential therapeutic target for future therapies that may address the handicap in cleavage of this important cardiac hormone. [Gaggin and Januzzi, 2014]

Plastic tubes containing ethylenedinitrotetraacetic acid (EDTA) are desirable for BNP determination and refrigeration is required if the interval between blood collection and analysis is over 4 hours; whereas NTproBNP can be measured in both serum or plasma, collected in glass or plastic tubes, and has no significant loss of immunoreactivity after 48 hours at room temperature. [?]

1.1.1 NPRs structure and function

There are three known natriuretic peptide binding proteins (natriuretic peptide receptors NPRs). All members contain a relatively large (450 amino acid) extracellular ligand binding domain and a single membrane-spanning region of about 20 residues. Natriuretic peptide receptors A and B contain an equally large intracellular domain consisting of a so-called kinase homology domain, dimerization domain, and carboxyl-terminal guanylyl cyclase domain. Thus, NPR-A and NPR-B signal by catalyzing the synthesis of the intracellular signaling molecule cGMP. In contrast, NPR-C only contains a 37 residue intracellular domain and lacks guanylyl cyclase activity. It primarily controls local natriuretic peptide concentrations via receptor-mediated internalization

and degradation. see fig.6 [Rose and Giles, 2008].

NPR-A and NPR-B are generally considered to mediate all known biological actions throughout the guanylate cyclase (GC) intracellular domain, while the third member of the natriuretic peptide receptor family, the NPR-C receptor, does not have a GC domain. The GC receptors for ANP/BNP (NPR-GC-A) and CNP (NPR-GC-B) belong to a family of seven isoforms of transmembrane enzymes (from GC-A to GC-G), which all convert guanosine triphosphate into the second messenger cyclic 3',5'-guanosine monophosphate (cGMP). The physiological expression of NPR-A and NPR-B differs quite significantly in human tissues. NPR-A is found in abundance in larger, conduit blood vessels, whereas the NPR-B is found predominantly in the central nervous system. Both receptors have been localized in adrenal glands and kidney [Ahluwalia et al., 2004].

The affinity for ANP, BNP and CNP also varies greatly among the different NPRs. ANP shows a greater affinity for NPR-A and NPR-C, and CNP for NPR-B, while BNP shows a lower affinity for all NPRs compared to the other two peptides. Activation of the GC-linked NPRs is incompletely understood [Fan et al., 2005a].

ANP and BNP interact with these NPRs (A,B and C) with their main physiologic effects exerted through the NPR-A receptor. The NPR-A is the predominant form on the blood vessels, with a smaller amount of NPR-B, and both receptors are found in the kidneys and adrenal glands. ANP and BNP binding to NPR-A and NPR-B leads to activation of guanylyl cyclase GC and downstream signaling through cyclic guanosine monophosphate (cGMP). NPR-C clears ANP, and to a lesser extent, BNP by binding and internalizing the receptor and degrading the hormone. see fig.2 [Maisel and Wettersten, 2018]

The stoichiometry of the ligand-receptor complex is 1:2 [Ogawa et al., 2004].




Figure 6: CAPTION Schematic representation of natriuretic receptors

Although ligand-dependent internalization and degradation of NPR-A has been intensely studied by several groups for many years, a consensus understanding of the importance of this process in the regulation of NPRs has not emerged. Early studies conducted on pheochromocytoma cells suggested that both NPR-A and NPR-C internalize ANP and that both receptors are recycled back to the cell surface. Other studies, have reported that ANP binding to NPR-A stimulates its internalization, which results in the majority of the receptors being degraded with a smaller portion being recycled to the plasma membrane. In contrast, other studies reported that NPR-A is a constitutively membrane resident protein that neither undergoes endocytosis nor mediates lysosomal hydrolysis of ANP. These studies did not support the hypothesis that down-regulation is responsible for NPR desensitization observed in response to various physiological or pathological stimuli [Joubert et al., 2001].

NPR-A internalization and degradation is also controversial. One group consistently reports that the majority of internalized ANP-NPR-A complexes are degraded via a lysosomal pathway with a small portion

returning intact to the plasma membrane [Pandey, 2002]. Meanwhile, studies in primary kidney and Chinese Hamster ovary indicate that NPR-A is a membrane resident protein that does not undergo acute internalization and degradation [Fan et al., 2005b] [Vieira et al., 2001].

It is generally thought that the NPR-C is not linked to GC and so serves as a clearance receptor [Clerico and Emdin, 2004]

NPR-C is present in higher concentration than NPR-A or NPR-B in several tissues (especially vascular tissue), and it is known constitutively to internalize NPs [Fan et al., 2005a].

However, the NPR-C receptor could be coupled to a G-protein that inhibits cyclic AMP synthesis. These receptors, which are present in great amount especially on the endothelial cell wall, may mediate some paracrine effects of CNP on vascular tissue [Ahluwalia et al., 2004].

physiologic functions

Cardiac natriuretic hormones have powerful physiological effects on the cardiovascular system, body fluid, and electrolyte homeostasis. NPs share a direct diuretic, natriuretic and vasodilator effect and an inhibitory action on ventricular myocyte contraction as well as remodeling and inflammatory processes of myocardium and smooth muscle cells [Clerico and Emdin, 2004].

NPs induce actions that reduce cardiac preload and afterload to counteract the detrimental effects of pressure and volume overload, as seen in HF. These physiologic processes are counter-regulatory to the detrimental neurohormonal activation of the sympathetic nervous system and RAAS in HF and are why ANP and BNP levels reflect HF severity. [Potter, 2011]

Circulating BNP acts as an antagonist of the renin angiotensin aldosterone system, and protects the body from plasma overload by in-

ducing diuresis, natriuresis, vascular dilatation and inhibition of the sympathetic nervous system. [Hall, 2005]

Mice with reduced cardiomyocyte expression of NPR-A exhibited moderate hypertrophy even though they were slightly hypotensive [Patel et al., 2005].

Targeted deletion of BNP resulted in normotensive mice with normal heart size but with increased ventricular fibrosis - especially when subjected to pressure overload [Tamura et al., 2000].

Although prolonged hypertension can cause hypertrophy, the level of hypertrophy in NPR-A deficient mice is significantly greater than that observed in other genetic models that cause similar levels of hypertension, suggesting that NPR-A elicits a local growth inhibitory signal in the heart. Data for this idea was initially shown in NPR-A knockout mice, which have enlarged hearts even when effectively treated with antihypertensive drugs from birth [Knowles et al., 2001].

Transgenic rats expressing a dominant negative form of NPR-B exhibit mild blood pressure-independent cardiac hypertrophy and increased heart rate [Langenickel et al., 2006].

The ability of the ANP/NPR-A pathway to increase endothelial permeability is supported by the observation that hematocrit levels are elevated prior to urination and are preserved in nephrectomized animals. Furthermore, mice with genetically engineered reductions of NPR-A in vascular endothelium exhibit volume expansion, hypertension, and reduced albumin clearance from the vascular system [Sabrane et al., 2005].

Physiological experiments involving mice with severe reductions of NPR-A in vascular smooth muscle cells demonstrated that while smooth muscle NPR-A is required for acute ANP- or BNP-dependent vasorelaxation, this response does not play a significant role in controlling

chronic blood pressure [Holtwick et al., 2002].

The function of natriuretic peptides was also studied after induction of myocardial infarction in KO mice lacking the NPR-A, the receptor for ANP and BNP. KO and wild-type mice were subjected to left coronary artery ligation and then followed-up for 4 weeks. KO mice showed significantly higher mortality because of a higher incidence of acute HF, which was associated with diminished water and sodium excretion and with higher cardiac levels of mRNAs encoding ANP, BNP, TGF- β 1, and type I collagen. By 4 weeks after infarction, left ventricular remodeling, including myocardial hypertrophy and fibrosis, and impairment of left ventricular systolic function were significantly more severe in KO than wild-type mice. These data confirm that the NPs system has powerful anti-remodeling properties on ventricular cardiomyocytes.[Nakanishi et al., 2005]

In transgenic mice with overexpression of ANP and BNP in liver, plasma ANP and BNP levels are from 10- to 100-fold higher than in control mice, with a blood pressure of 20-25 mmHg lower. These mice also have lighter hearts, but with the same cardiac output and rate, than controls. On the other hand, ANP KO mice develop NaCl-sensitive hypertension. Transgenic mice overexpressing the NPRA gene have a lower blood pressure than wild-type mice. NPR-A KO mice show an increase in blood pressure compared with controls (on average 10 mmHg in heterozygous and 30 mmHg in homozygous animals), which is not affected by NaCl intake. These data suggest a different pathophysiological mechanism for hypertension between KO mice for the ANP gene and its specific receptor; this difference does not yet have an explanation. NPRC heterozygous KO mice do not show blood pressure variation, whereas homozygous mice show on average a decrease in blood pressure of about 8 mmHg [Nakayama, 2005].

It is theoretically conceivable that ANP and BNP act like hormones in vascular tissue by reaching the smooth muscle cells from the circulation after secretion by the heart, while CNP shows a paracrine action, being

secreted by endothelial cells [Woodard et al., 2002]

The endocrine action, shared by plasma ANP and BNP, can be enhanced by natriuretic peptides produced locally in target tissues (paracrine action). Endothelial cells synthesize CNP, which in turn exerts a paracrine action on vessels [Qian et al., 2002].

In addition, CNP infusion was shown to reduce cardiac remodeling in response to experimentally induced myocardial infarction in rats, and transgenic expression of CNP improved outcomes in mice subjected to ischemia/reperfusion injury or myocardial infarction [Wang et al., 2007].

Evidence from cellular, animal, and human studies suggests that all NPs are able to stimulate NO production by endothelial NO synthase (eNOS); this effect is probably mediated by clearance receptor NPR-C. Stimulation of this NPR-C receptor results in decreased cAMP levels by adenylyl cyclase inhibition through an inhibitory guanine nucleotide-regulating protein [Houben et al., 2005].

ANP expression is markedly upregulated in eNOS $-/-$ mice, and exogenous ANP restores ventricular relaxation in wild-type mice treated with NOS inhibitors. These data suggest that the NPs and NO systems are linked by a negative feedback mechanism. [Gyurko et al., 2000]

NPs exert a protective effect on endothelial function by decreasing shear stress, modulating coagulation and fibrinolysis pathways, and inhibiting platelet activation. They can also inhibit vascular remodeling process as well as coronary restenosis post-angioplasty [Nakanishi et al., 2005].

CNP has little natriuretic and diuretic action compared to ANP or BNP, it is capable of modulating the vascular effects of the local RAAS by opposing potent vasoconstriction to angiotensin II [Han and Hasin,

2003].

On the other hand, endothelin-1 (ET-1) induces an increase in the number of endothelial cells that secrete CNP. Therefore, the parallel production and activity of vasodilator CNP and vasoconstrictors such as ET-1 and angiotensin II allows for tight local regulation of these vasoactive peptides and thus blood flow [Evans et al., 2002].

Thrombus formation is suppressed significantly in the presence of CNP, which indicates that inhibition of coagulation might contribute to the vasoprotective properties of this peptide. Observations that CNP blocks platelet aggregation, induced by thrombin, confirm that endothelium-derived CNP also exerts an anti-thrombotic effect [Ahluwalia and AJ, 2005].

Renal tubular cells produce urodilatin, another member of the peptide natriuretic family, which has powerful diuretic and natriuretic properties. [Vesely, 2003]

None cardiovascular functions

Humans with two loss-of-function alleles for NPR-B suffer from a rare type of autosomal recessive dwarfism, called acromesomelic dysplasia, type Maroteaux. These individuals are characterized by disproportionate limb to torso ratios that are only obvious a year or more after birth. [Bartels et al., 2004]

Single copy carriers of a nonfunctional NPR-B allele do not suffer from disease but, they are statistically shorter than comparable individuals with two wild type NPR-B alleles [Olney et al., 2006].

The most obvious function of the CNP/NPR-B pathway is to stimulate long bone growth. Though undetectable at birth, mice lacking functional CNP or NPR-B develop dwarfism due to impaired endochondrial ossification [Tsuji and Kunieda, 2005].

NPR-B dominant negative mutant transgenic rats, in addition to mild growth retardation of the long bones, displayed progressive, blood pressure-independent cardiac hypertrophy and an elevated heart rate [Langenickel et al., 2006].

NPR-B and/or its mRNA is expressed in bone, brain, fibroblasts, heart, kidney, liver, lung, uterine, and vascular smooth muscle tissue. [Dickey et al., 2007]

Transgenic CNP overexpression or reduced degradation of CNP due to loss-of-function mutations in NPR-C result in skeletal overgrowth [Yasoda et al., 2004].

Furthermore, the inter-relationships between the NPs system and pro-inflammatory cytokines suggest that NPs play an important role in mechanisms responsible for cardiac and vascular adaptation, maladaptation and remodeling in response to various physiological and pathological stimuli [Walther et al., 2003].

Huge amount of data strongly supports the hypothesis that NPs are active components of the body integrative network that includes nervous, endocrine and immune systems. This hypothesis implies that there are two counteracting systems in the body: one has sodium-retaining, vasoconstrictive, thrombophylic, pro-inflammatory and hypertrophic actions, while the second one promotes natriuresis and vasodilatation, and inhibits thrombosis, inflammation and hypertrophy. NPs are the main effectors of the latter system, and work in concert with NO, some prostaglandins, and other vasodilator peptides [Booz, 2005].

Several reports have shown that NPs stimulate the synthesis and release of testosterone in a dose-dependent manner in isolated and purified normal Leydig cells. It has been suggested that this effect on normal Leydig cell steroidogenesis does not involve classical mechanisms of cAMP-mediated regulation of steroidogenic activity by gonadotropins. The stimulated levels of testosterone production by ANP, BNP, and

gonadotropins were comparable, whereas CNP has been found to be a weak stimulator of testosterone production in Leydig cells. Moreover, testicular cells contain immunoreactive ANP-like materials and a high density of natriuretic peptide receptor-A (NRP-A). These findings suggest that NPs play paracrine and/or autocrine roles in testis and testicular cells. Furthermore, the presence of ANP and its receptors has been reported in ovarian cells, too. Increasing evidence strongly support that NPs are present and probably locally synthesized in ovarian cells of different mammalian species and also play an important physiological role in stimulating estradiol synthesis and secretion in the female gonad [Pandey, 2005].

A review by [Waschek, 2004] has highlighted a possible major role for NPs in the development of certain systems, in particular skeleton, brain, and vessels. This review cites studies showing severe skeletal defects and impaired recovery after vascular and renal injury in NPs transgenic and knockout mice. In addition, NPs may have a role in the regulation of proliferation, survival, and neurite outgrowth of cultured neuronal and/or glial cells.

Genes for natriuretic peptides (including ANP, BNP and CNP) are also expressed in the central nervous system, where they likely act as neurotransmitters and/or neuromodulators [Vesely, 2003].

It was demonstrated that intranasal ANP acts as central nervous inhibitor of the hypothalamus pituitary-adrenal stress system in humans [Perras et al., 2004].

Co-expression of NPs and of their receptors was observed in rat thymus cells and macrophages, suggesting that NPs may have immunomodulatory and anti-inflammatory functions in mammals [Vollmar and AK, 2001].

Evidence for a role of NPs in the immune system is given by the fact that peptide hormones and their receptors are expressed in various

immune organs. Furthermore, several studies indicated that the NPs system in immune cells underlies specific regulatory mechanisms by affecting the innate as well as the adaptive immune response. In particular, ANP increases phagocytotic activity and production of reactive oxygen species of phagocytes. ANP affects the induced innate immune response by regulating the activation of macrophages at various stages. It also reduces production of pro-inflammatory mediators by inhibition of iNOS and COX-2 as well as TNF- α synthesis. ANP also affects TNF- α action, i.e. it interferes with the inflammatory effects of TNF- α on the endothelium. The peptide hormone counteracts TNF- α -induced endothelial permeability and adhesion and attraction of inflammatory cells. Finally, it affects thymopoiesis and T cell maturation by acting on dendritic cells and regulates the balance between TH1 and TH2 responses [Vollmar, 2005].

1.1.2 NPs in disease states

It is well known that changes in hemodynamic parameters (such as left ventricular ejection fraction, EF) and plasma NPs levels (expressed in a log scale) are closely related in patients with cardiovascular diseases [Bettencourt, 2004].

The NPs system activation is modulated not only by hemodynamic factors, but also by the activity of the counter-regulatory neuro-hormonal system. Consequently, it is likely that very small changes in hemodynamics, not assessable by echocardiographic examination, may produce significant (and measurable) variations in plasma concentrations of NPs [Emdin et al., 2004].

On average, the response of the NPs system to the increasing challenge of disease severity may not be linear. The curve reported in Figure 4 suggests that the NPs system responds with a sharp increase in BNP plasma concentration in the early phase of HF (NYHA class I-II

patients), followed, with the clinical progression of the disease, by a blunted increase (NYHA class III), and finally by a plateau (NYHA class IV) [Clerico et al., 2000].

Patients with HF show a progressive and parallel increase in NPs levels and in some neuro-hormones and cytokines. This increase can be closely related to disease severity, as assessed by functional NYHA class. Plasma BNP values, normalized by mean values found in healthy subjects, are significantly higher than other normalized neuro-hormone and cytokine values in HF [Emdin et al., 2004].

Patients with chronic HF show increased NPs plasma levels compared to normal subjects. These findings have been defined the "endocrine paradox" in HF, i.e., extremely high circulating levels of hormones with powerful natriuretic activity in patients with congestive HF, who show physical signs of fluid retention and vasoconstriction due to a relatively poor biological activity of the NPs system [Goetze, 2004b].

A blunted natriuretic response after pharmacological doses of ANP and BNP has been observed in experimental models and in patients with chronic HF, suggesting a resistance to the biological effects of NPs, principally natriuresis. This resistance syndrome was also demonstrated by in vivo turnover studies using radioactive tracers in patients with HF [Clerico et al., 2000].

Studies demonstrated that the activation of the neuro-hormonal system accelerates the left ventricular functional impairment in patients with HF. Drugs that contrast the detrimental effects of the neuro-hormonal system activation play a key role for the current pharmacological treatment of HF. Some of these, such as ACE inhibitors, angiotensin II receptor blockers, β -blockers, and spironolactone decrease the circulating levels of NPs,"normalize" their kinetics, and increase their biological activity [Clerico and Emdin, 2004].

Furthermore, they enhance the natriuretic effect of ANP or BNP analogs

administered to patients. In other words, the treatment with this type of pharmacological agents decreases the systemic resistance to the biological effects of NPs [Clerico et al., 2000].

Individual differences in the ability of heart tissue to mature the precursor of NPs peptides, or of peripheral tissues to degrade them, may help to explain why there are some differences in the clinical presentation among patients with HF with similar clinical severity and ventricular function [Goetze, 2004b].

A resistance to the biological action of NPs may be theoretically due to an increase in degradation (turnover) of circulating biologically active peptides. NPs are degraded *in vivo* and *in vitro* by several types of proteolytic enzymes, including serin-proteases, peptidyl arginine aldehyde proteases, kallikrein like proteases, and neutral endopeptidases (NEP) [Panteghini and Clerico, 2004].

Some peptides, derived *in vivo* or *in vitro* from degradation of intact proBNP, are biologically inactive, although they can be measured by immunoassay methods. Since the circulating levels of intact proBNP and of its derived peptides increase progressively with severity of HF, immunoassay methods can greatly overestimate the true biological activity of NPs in patients with severe HF. Unfortunately, at present, it is not possible to estimate the inaccuracy of NPs immunoassays because these methods use different, not standardized antibodies and calibrators, leading to highly different clinical results [Goetze, 2004b].

Another well-characterized deactivation mechanism is the process by which an activated receptor is turned off, commonly referred to as "desensitization". Phosphorylation of the intracellular kinase homology domain of NRP-A and NPR-B is required for hormone-dependent activation of the receptor, while dephosphorylation at this site causes desensitization. Deactivation of the NPs system via desensitization of NRP-A and NPR-B can occur in response to various pathophysiological stimuli [Fan et al., 2004].

NPR-B dephosphorylation has been shown to mediate desensitization in response to prolonged CNP exposure, protein kinase C activation, and intracellular calcium elevations [Potthast et al., 2004].

Some studies suggest that the resistance to biological effects of NPs in HF may be due, in part, to variations in the relative amount of the three different types of natriuretic peptide-specific receptors. In particular, there could be an upregulation of type C receptors (NPR-C) with a parallel down regulation of type A and B receptors (NPR-A and NPR-B) [Kuhn et al., 2004].

NPR-A and NPR-B mediate all known hormonal actions of NPs, therefore their down-regulation should induce a deactivation of the NPs system. The upregulation of NPR-C receptors that strongly contribute to the clearance of biologically active peptides could further increase the resistance to NPs in patients with HF [Andreassi et al., 2001].

Reversal of cardiomyocyte hypertrophy during left ventricular assist device support was accompanied by normalization of ANP, BNP and NPR-C mRNA levels and a significant recovery of responsiveness to ANP [Kuhn et al., 2004].

However, [Fan et al., 2004] found that neither NPR-A nor NPR-B were internalized or degraded in response to natriuretic peptide binding in cultured cells.

It is important to note that renal function can affect the biological action of NPs in different ways. NPs are small peptides freely filtrated by renal glomerulus; the kidneys are probably responsible for about 50% of metabolic clearance rate of plasma ANP and BNP and in this way renal diseases can affect the circulating levels of NPs. Indeed, a decreased renal function greatly increases the plasma NPs concentration and consequently more peptide hormones are available for other target tissues (such as brain, vascular tissue, adrenal gland and so on) [Clerico and Emdin, 2004].

Luminal perfusion with ANP has been shown to reduce sodium efflux from the inner medullar collecting duct, suggesting that this hormone has also luminal sites of action. As a consequence, a reduction in the filtration can potentially induce renal hypo-responsiveness to NPs [Charloux et al., 2003].

A peripheral resistance to the biological effects of NPs may play an important role in other clinical conditions, besides HF. For example, NPR-C is also present on cellular membranes of adipose tissue. It was suggested that the increase in NPR-C receptors observed in obese subjects can in turn increase the peripheral degradation of NPs and consequently blunt the action of the NPs system. This reduced activity of the NPs system may increase the risk of developing arterial hypertension and other cardiovascular diseases due to the non-contrasted and therefore prevailing effects of the counter regulatory system with sodium-retentive and vasoconstrictive properties [Sarzani et al., 2004].

1.2 clinical applications

1.2.1 utility in diagnosis

In heart failure

NTproBNP is correlated with several echocardiographic indicators of cardiac structure and function including:

- Left ventricular (LV) end-diastolic wall stress
- LV ejection fraction (LVEF)
- E/e'
- LV longitudinal strain

- LV circumferential strain
- Left atrial dimensions
- Right ventricular ejection fraction
- Right ventricular pressures

[Richards, 2018]

[Iwanaga et al., 2006] measured systolic and diastolic wall stress by echocardiography and cardiac catheterization, and related this key measurement to plasma concentrations of NP in patients with HF. A striking correlation between plasma BNP with end-diastolic wall stress ($r = 0.887$; $P < 0.001$) seemed to be far stronger than the correlation with LV end-diastolic pressure ($r = 0.296$; $P < 0.001$). NP levels seem to reflect LV wall stress more closely than other ventricular parameters in HF, and this relationship may better account for interindividual differences in plasma NP values than other measures.

It is well known that changes in hemodynamic parameters (such as left ventricular ejection fraction, EF) and plasma NPs levels (expressed in a log scale) are closely related in patients with cardiovascular diseases. Yet the NPs system activation is modulated not only by hemodynamic factors, but also by the activity of the counter-regulatory neurohormonal system. Consequently, it is likely that very small changes in hemodynamics, not assessable by echocardiographic examination, may produce significant (and measurable) variations in plasma concentrations of NPs [Emdin et al., 2004].

The relationship between cardiac structure and function and associated cardiac transmural distending pressures and myocyte stretch on the one hand with cardiac release and plasma concentrations of NTproBNP on the other underpins the strength of NTproBNP as a biomarker in HF. NTproBNP has good diagnostic performance for discrimination of

acute heart failure among patients presenting with new-onset dyspnea. [Richards, 2018]

In a study of 305 patients assessed by 92 family doctors for suspected incipient heart failure (on the basis of exertional dyspnea and/or peripheral edema), the addition of plasma NTproBNP measurements to clinical history and examination, significantly improved diagnostic accuracy by 10 patients per 100 assessed. [Wright et al., 2003]

The Breathing Not Properly Multinational Study published in 2002 was the first large study to evaluate the efficacy of BNP as a cardiac biomarker for diagnosis of HF in the ED setting. This study evaluated 1586 patients presenting to EDs with the chief complaint of dyspnea at different medical centers around the world. Serum BNP levels were higher in patients presenting with dyspnea caused by AHF than in dyspnea from a noncardiac cause (mean 675 ± 450 vs 110 ± 225 pg/mL, $P < .001$). Serum BNP levels were positively correlated with severity of HF using the New York Heart Association (NYHA) classification. In addition, BNP concentrations were directly associated with increasing severity of HF symptoms. The diagnostic accuracy of a BNP measurement surpassed any other single findings from routine evaluation including history and physical examination, chest x-ray, or laboratory tests in identifying HF as the cause of dyspnea. BNP performed better than established clinical HF criteria and added independent information to the traditional evaluation of these patients. By means of receiver operating characteristics analyses, a BNP value of 100 pg/ml was the optimal value to differentiate patients with dyspnoea caused by HF from dyspnoea due to pulmonary pathology (area under the curve (AUC) was 0.91, sensitivity 90%, specificity 76%, and accuracy 85%) Fig. 7. This value of 100 pg/ml also discriminated non-systolic HF (LVEF $\leq 45\%$) from non-HF patients at the emergency department. Using a cutoff of 50 pg/mL, BNP had a negative predictive value of 96%. [Maisel et al., 2002]

In a cohort of 600 patients presenting with dyspnea to the emergency

department, the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study showed that patients with ADHF had much higher NTproBNP concentrations compared with patients without HF (median 4054 vs 131 pg/mL, $P < .001$) and higher NTproBNP concentrations were also directly associated with increasing severity of HF ($P=0.001$). Of all single traditional HF evaluation techniques, NTproBNP was the strongest predictor of the diagnosis of ADHF. The diagnostic accuracy of NTproBNP was stronger than that of clinical judgment alone (AUC of 0.94 vs 0.90), but the best way to accurately diagnose ADHF was by using a combination of NTproBNP and clinical judgment (AUC 0.96). Using a cutoff level of 300 pg/mL, and NTproBNP was 90% sensitive and 85% specific for diagnosis of AHF. A single NTproBNP cutoff value of 900 pg/mL provided identical performance to that reported for a BNP value of 100 pg/mL. Fig. 8 [Januzzi et al., 2005]

In their subsequent study (The International Collaboration on NT-proBNP study (ICON)) [Januzzi et al., 2006b] included data on 1256 patients presenting with new-onset shortness of breath. ICON data defined the sensitivity, specificity, negative predictive value, positive predictive value, and overall accuracy of NTproBNP for the diagnosis of acute HF in acutely symptomatic patients. Plasma NTproBNP of 300 pg/mL acts as an excellent rule-out threshold with a sensitivity for ADHF consistently greater than 90% and a negative predictive value of 98%. Specificity is improved by using a 3-tiered age-stratification approach for cutoff points with 450, 900, and 1800 pg/mL performing well for age groups less than 50, 50 to 75, and greater than 75 years, respectively with 90% sensitivity and 84% specificity for acute HF. Fig. 9

The typical elevation of plasma NTproBNP in the setting of severe symptomatic acute decompensated heart failure (ADHF) is so pronounced (median values are >5000 pg/mL and are typically >40 -fold greater than the levels observed in controls without HF) that this marker achieves an excellent "signal-to-noise ratio" for ADHF.




Figure 7: CAPTION ROC curves for BNP in the diagnosis of heart failure at the emergency department [Januzzi et al., 2005].




Figure 8: CAPTION ROC curves for NTproBNP in the diagnosis of heart failure at the emergency department.[Januzzi et al., 2005]

Optimal NT-proBNP cutpoints for the diagnosis of heart failure in outpatients

Category	Optimal Cutpoint (pg/mL)
Exclusionary “rule out” cutpoint all patients (n = 1256)	300
Confirmatory (“rule-in”) cutpoints	
<50 y (n = 184)	450
50–75 y (n = 537)	900
>75 y (n = 535)	1800
Rule-in, overall (n = 1256)	—

Figure 9: CAPTION Abbreviations: NTproBNP, amino-terminal pro-B-type natriuretic peptide; NPV, negative predictive value; PPV, positive predictive value.[Januzzi et al., 2006b]

Median plasma concentrations of NT-proBNP

Category of Heart Failure	NT-proBNP Me (pg/mL)
Acute decompensated heart failure	
HFrEF	6356
HFpEF	3070
Chronic heart failure	
HFrEF	895
HFpEF	339

Figure 10: CAPTION Abbreviations: HFpEF, heart failure with preserved left ventricular ejection fraction; HFrEF, heart failure with reduced left ventricular ejection fraction; NTproBNP, amino-terminal pro-B-type natriuretic peptide. [Richards, 2018]

[Richards, 2018]

The evidence is now overwhelming that early measurement of serum BNP levels should be used to diagnose acute heart failure (AHF), and it is a class I indication in the American Heart Association (AHA)/American College of Cardiology (ACC) guidelines for the management of HF that BNP levels should be measured in all hospital admissions for AHF. Cardiac-specific biomarkers are particularly useful in the emergency department (ED) setting when evaluating dyspneic patients, because it is difficult to distinguish between shortness of breath caused by HF versus that caused by pulmonary disease. [Maisel and Wettersten, 2018]

Cardiac chamber wall stress, the prime driver of NP synthesis and release, in accord with the law of Laplace, is directly related to intrachamber pressure and chamber radius and inversely related to wall thickness. In concentrically hypertrophied hearts, as commonly observed in patients with HF with preserved ejection fraction (HFpEF), unit wall stress is less than in those patients with HF with reduced ejection fraction (HFrEF) and dilated left ventricles. Accordingly, plasma NP in acute decompensated HF (ADHF) are lower in HFpEF compared with HFrEF. [Richards, 2018]

Plasma NP concentrations reflect aspects of diastolic dysfunction independent of age, sex, renal function, body mass index, and LVEF. Plasma NTproBNP (>600 pg/mL) and BNP (>100 pg/mL) are strong, albeit relatively nonspecific, independent predictors of restrictive filling the most severe grade diastolic dysfunction. In HF, plasma NTproBNP correlates with E/e' , a well-validated index of LV filling pressures, in addition to measures of LV compliance, myocardial relaxation, and left atrial dimensions. With respect to right heart function, plasma concentrations of B-type NPs are inversely related to right ventricular ejection fraction and directly related to right ventricular dimensions and estimated intraventricular pressures. [Troughton and Richards, 2009]

An echocardiographic substudy of the phase II PARAMOUNT trial (LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction) of valsartan-sacubitril therapy in HFpEF, demonstrated decreases in LV systolic longitudinal and circumferential strain that were significantly related to plasma NTproBNP independent of age, sex, systolic and diastolic blood pressures, body mass index, LVEF, left atrial volume index, E/E', atrial fibrillation (AF), or renal function. [Kraigher-Krainer et al., 2014]

Despite BNP and NTproBNP concentrations being typically lower in HF patients with preserved ejection fraction (HFpEF) compared with HF patients with reduced EF (HFrEF), the same respective cutoff points for BNP and NTproBNP have been shown to diagnose ADHF accurately regardless of EF, albeit with a slightly reduced sensitivity for HFpEF. Clinicians should be aware of the potential for a "false negative" result for both peptides in this setting, therefore. [Maisel et al., 2003]

In the setting of incipient or treated HF, NP values often fall into the subdiagnostic range and this is particularly so in HFpEF. This emphasizes the need to apply the recommended cutpoint values for acute HF in the appropriate setting; that is, with new onset of distressing breathlessness where acute HF is likely. When NPs fall into the "gray zone" between rule out and rule in values for acute HF echocardiography is an invaluable diagnostic adjunct with elevated E/e' and/or the presence of a restrictive filling pattern helping securing the diagnosis of HF. [Richards, 2018]

In acute coronary syndrome

Elevated levels of BNP and NTproBNP, traditionally thought of as HF biomarkers, have been detected in patients with ACS. [Morita et al., 1993] examined BNP levels in patients presenting with suspected ACS and found that BNP concentrations were elevated in patients with MI

compared with those without (mean 92 vs 5.2 pg/mL on presentation, $P<.01$) and peaking at a mean level of 319 pg/mL about 16 hours after admission. The extent of BNP or NTproBNP elevation seemed to be related to the degree of infarct size and myocardial dysfunction. [Morita et al., 1993]

Circulating levels of NPs increase after acute myocardial infarction (AMI); the extent of the increase is related to the size of the infarct. Patients with smaller infarcts tend to have a monophasic increase in plasma BNP, peaking at 20 hours after the onset of symptoms; on the other hand, those with larger infarcts, lower EF, and clinical signs of HF may present a further peak at 5 days after admission. Other studies are less convincing regarding the ability of the NPs assay to identify patients with significant myocardial dysfunction after AMI [Panteghini et al., 2003]. These conflicting results could be due to the differences in sample collection time, type of NPs (ANP, BNP, or NTproBNP) measured, type of assay, and inclusion criteria adopted. However, persisting elevation of NPs levels at 1 or 2 months after AMI usually suggests a high risk of adverse remodeling and subsequent HF [Clerico and Emdin, 2004].

The diagnostic accuracy of the BNP assay in patients with myocardial infarction was evaluated in the meta-analysis by [Doust et al., 2004] taking into account only two studies. They found the pooled odds ratio to be 9.4 (95% confidence interval 4.5-19.4).

[Foote et al., 2004] measured NT proBNP and BNP in blood samples from a group of normal volunteers, and two groups of patients, one with and the other without coronary artery disease, before and after maximal exercise. Post-exercise increases in NTproBNP and BNP were approximately 4-fold higher in the ischemic group than in the nonischemic group; while in volunteers, the increase was almost identical to that of the non-ischemic patient group. At equal specificity to the ECG (58.8%), the sensitivities of the BNP/NTproBNP assay in detecting ischemia were 90 and 80%, respectively; in contrast, the

sensitivity of the exercise ECG was only 37.5%.

In the study by [Sabatine et al., 2004], transient myocardial ischemia was associated with an immediate rise in circulating BNP levels, and the magnitude of the rise was proportional to the severity of ischemia. These findings demonstrate an important link between the severity of an acute ischemic insult and the circulating levels of BNP. However, further studies are necessary to evaluate the relevance of the BNP/NTproBNP assay.

The diagnostic use of NTproBNP in patients presenting with acute chest pain was evaluated in 328 patients from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial. Patients with ACS had higher concentrations of NTproBNP, conventional cardiac troponin T (cTnT), highly sensitive cardiac troponin T (hsTnT), and MR-proANP; adding NTproBNP to either cardiac troponin improved diagnostic performance for ACS by correctly reclassifying events. The best approach was in a dual-negative marker strategy with improved sensitivity and negative predictive value for ACS on presentation with a single time measurement (sensitivity: cTnT from 38% to 83%–86%, hsTnT from 59% to 86%–90%; all $P < .01$ and negative predictive value: cTnT from 94% to 97%–98%, hsTnT from 96% to 97%–98%). [Truong et al., 2012]

The widely accepted reason behind NP elevation is increased wall tension due to LV systolic or diastolic dysfunction caused by myocardial ischemia through rapid induction of BNP gene expression. However, there are data to suggest that BNP and NTproBNP may be directly released from cardiomyocytes in response to myocardial ischemia regardless of ventricular wall stress. Theories abound regarding cause, including the activation of the inflammatory pathway; similar to some of the acute phase reactants. Most studies for NP in ACS have been with regards to risk stratification, whereas few studies have evaluated its role in diagnosis of ACS in combination with the standard of care biomarker, cardiac troponins. [Gaggin and Januzzi, 2014]

In primary care and screening

Most studies evaluating the use of BNP and NTproBNP in the out-patient setting have focused on the negative predictive value of either peptide to exclude HF. Using lower optimal cutoff points of less than 40 pg/mL for BNP, and less than 50 pg/mL for age less than 50 years, less than 75 pg/mL for ages 50–75 years, and less than 250 pg/mL for age greater than 75 years for NTproBNP, negative predictive values approach 95% to 99%. In those with elevated values, to determine a diagnosis of HF, however, further evaluation such as echocardiography is needed. In patients without any symptoms, BNP or NTproBNP may potentially be used for the purpose of screening at-risk patients for the presence of underlying structural heart disease; they have been found to be useful for both reduced LV function and diastolic ventricular dysfunction. [Gaggin and Januzzi, 2014]

In patients with chronic HF, the NTproBNP assay reflects functional cardiac impairment and decreased exercise capacity (measured by peak exercise oxygen consumption) better than the left ventricular EF. [Williams et al., 2004]

However diagnostic sensitivity of BNP/NTproBNP assays in detecting left ventricular systolic dysfunction could be suboptimal in asymptomatic or low-risk individuals, especially in women [Vasan et al., 2002].

[Wright et al., 2003] evaluated the effect of NTproBNP assay on the clinical diagnostic accuracy of HF in primary care by means of a prospective, randomized controlled trial in 305 patients. Each patient was randomized in two groups, one in which the general practitioner had at their disposal the NTproBNP assay results (NTproBNP assay group), while the other did not (control group). The diagnostic accuracy improved by 21% in the NTproBNP assay group and by 8% in the control group ($p = 0.002$). This study indicates that NTproBNP measurement significantly improves the clinical diagnostic accuracy of

HF in general practice.

[Vasan et al., 2002] analyzed the Framingham Heart Study cohort (3,177 individuals) using BNP and NT-proANP in the evaluation of left ventricular hypertrophy and systolic dysfunction in a community population. The presence of the disease was evaluated by using echocardiographic findings (the prevalence of left ventricular systolic dysfunction was 9.3% in the 1,470 men and 2.5% in the 1,707 women tested, respectively). The area under the curve (AUC) of receiver operating characteristic (ROC) analysis for NPs assay for identifying both left ventricular hypertrophy and systolic dysfunction was on average about 0.75, with a good specificity (assumed 95% both for men and women) and negative predictive value (NPV, on average ranging from 92% to 97% in men, and from 91% to 98% in women), but a poor sensitivity (i.e., ranging from 27% to 28% in men, and from 13% to 40% in women) and positive predictive value (PPV, from 22% to 38% in men, and from 5% to 40% in women), using gender-related BNP cut-off values, indicating that the NPs assay may have only a limited usefulness as a screening method for HF in a general population, owing to the poor sensitivity and PPV but, may be used to rule out HF in an asymptomatic individual. [Vasan et al., 2002].

A meta-analysis showed that the odds ratio for diagnostic accuracy of BNP assay in different groups of patients with suspected HF is highly significant. In particular, the pooled diagnostic odds ratio, when clinical criteria were used as gold standard for HF, was 30.9 (95% confidence interval 27.0-35.4), while it fell to 11.9 (8.4-16.1) when a value $\leq 40\%$ of left ventricular EF, was used as reference standard. In populations with a higher prevalence of cardiac diseases, including only individuals with a clinical suspicion of HF, the diagnostic sensitivity of BNP can improve up to 95%, or even more, as long as appropriate cut-off values are selected [Doust et al., 2004].

Heart failure is primarily a disease of old age; chronic HF increases in prevalence with aging from $\approx 1\%$ in people aged ≤ 65 years to $> 5\%$ in

those >65 years of age, and this clinical condition is the first cause of morbidity and mortality in older people. [Baruch et al., 2004] demonstrated that elderly patients present with more advanced HF, as evidenced by their higher morbidity and mortality rate along with greater neurohormonal activation. According to these findings, elderly people should be considered to be a population with high risk for developing HF and so the BNP/NTproBNP assay may be useful as a screening test for HF in older age.

[Hutcheon et al., 2002] in a prospective study specifically evaluated the diagnostic accuracy for HF of BNP assay in 299 consecutive patients (mean age 79 years, 65% women) attending day-hospital over a period of 13 months. This study suggested that both BNP assay and ECG were sensitive in detecting left ventricular systolic dysfunction, but lacked specificity (but the combination of the two tests improved diagnostic accuracy).

[Ng et al., 2003] suggested that BNP assay together with the presence of major ECG abnormalities and history reduced by a factor of six the number of subjects requiring echocardiography to detect one case of myocardial dysfunction in a large population screening (1,360 patients tested).

In their study, [Nakamura et al., 2005] could identify several types of structural heart disease, in particular valvular heart disease, exclusively by BNP testing, suggesting that BNP measurement can make a significant contribution to screening for CHF precursors when used in combination with ECG in elderly populations (856 subjects enrolled, with age ≥ 65 years).

[Hedberg et al., 2004] reported that both the ECG and the plasma concentration of BNP were highly efficient in excluding left ventricular systolic dysfunction in 407 75-year-old subjects. However, compared with the BNP assay, the ECG yielded a lower number of false positive cases. In screening for left ventricular systolic dysfunction, the BNP

has a diagnostic value in addition to the ECG, but only in individuals with abnormal ECG [Hedberg et al., 2004].

[Ray et al., 2004] indicated that the BNP assay may be particularly useful in elderly patients, especially in differentiating cardiogenic pulmonary edema from respiratory causes of dyspnea.

Screening of populations with more than 1% prevalence of HF (such as people with age more than 60 years) with BNP followed by echocardiography should provide a health benefit at a cost that is comparable to or less than other accepted health interventions [Heidenreich et al., 2004].

[Valle et al., 2005] demonstrated that NTproBNP assay was useful for detecting HF among people living in elderly nursing homes.

Another example of the clinical relevance of BNP assay is the possibility of identifying HF caused by drug cardiotoxicity. Cardiotoxicity is a potential side-effect of some chemotherapeutic agents. The anthracycline class of cytotoxic antibiotics are the most famous, but other chemotherapeutic agents can also cause serious cardiotoxicity and are not so well recognized (including cyclophosphamide and fluorouracil) [Gharib and AK, 2002].

[Sandri et al., 2005] suggested that BNP/NTproBNP assay is a predictive marker of cardiac dysfunction in patients affected by aggressive malignancies and treated with high-dose chemotherapy. The acute release of circulating levels of troponin should be only a mirror of the death of myocytes, while the persistent increase in BNP, after several days or weeks from the administration of cardiotoxic drug, should be specifically related to ventricular remodeling and myocardial dysfunction.

BNP measurement may exclude normal heart with high probability owing to its high degree of sensitivity and NPV when used in screen-

ing high-risk populations, therefore reducing the echocardiographic diagnostic burden; this is the rationale for considering the BNP assay in the first step of an algorithm for the differential diagnosis of heart failure [Cowie and GF, 2002].

1.2.2 Cost-effectiveness

Because of the speed and ease of measuring serum biomarkers, use of BNP in EDs has the potential to greatly reduce hospital stay and overall treatment costs associated with HF. [Mueller et al., 2004] evaluated 452 patients presenting to the ED with acute dyspnea and found that measurement of BNP led to more rapid HF diagnosis, which reduced time to discharge and decreased overall cost of treatment associated with the ED visit.

The Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) study showed similar findings using NTproBNP in a population of 500 patients presenting to 7 different EDs in Canada. Measurement of serum NTproBNP level to aid in the diagnosis of HF reduced duration of ED visits by 21%, reduced the rate of rehospitalization after 60 days by 45%, and similarly reduced the overall cost of treatment of these patients. [Moe et al., 2007]

Beyond an improvement in diagnostic performance, adding information derived from these NP measurements appears to improve cost-effectiveness and resources utilization. Several studies including the B-type natriuretic peptide for Acute Shortness of breath Evaluation (BASEL) study, the IMPROVE-CHF, study and the PRIDE study, all showed cost savings with a diagnostic evaluation that included BNP or NTproBNP measurement. The BASEL study showed that the group with a diagnostic strategy involving BNP measurement had a decreased need for hospitalization and intensive care without excess

hazard. In the IMPROVE-CHF study, NTproBNP supplemented evaluation strategy was associated with better clinical outcomes as well. [Gaggin and Januzzi, 2014]

Nielsen et al. [Nielsen et al., 2003] sought to assess the cost-effectiveness of using plasma BNP as a pre-echocardiographic screening test for left ventricular systolic dysfunction in the general population. Screening high-risk subjects by BNP before echocardiography could reduce the cost per detected case of left ventricular systolic dysfunction by 26% for the cost ratio of 1/20 (BNP/echocardiogram). Greater reduced costs (up to 50%) can be predicted for the group of low-risk subjects [Nielsen et al., 2003].

Mueller et al. conducted a prospective, randomized, controlled study of 452 patients who presented to the emergency department with acute dyspnea: 225 patients were randomly assigned to a diagnostic strategy involving the measurement of BNP, and 227 were assessed in a standard manner. This study indicated that BNP assay improved the evaluation and treatment of patients with acute dyspnea and thereby reduced the time to discharge and the total cost of treatment in the emergency department [Mueller et al., 2004].

[Morimoto et al., 2004] conducted a cost-effectiveness analysis of regular BNP measurement in the outpatient setting. The target population was symptomatic CHF patients aged 35-85 years, discharged from the hospital. Intervention was BNP measurement once every 3 months (BNP group) or no BNP measurement (clinical group). The baseline analysis during the 9-month period after hospitalization suggested that the introduction of BNP measurement in heart failure management is not only cost-effective by reducing hospitalization, but also improves the outcome of patients, as assessed by (quality-adjusted life year) analysis [Morimoto et al., 2004].

However, the cost-effectiveness analysis strongly depends on the relative cost of the BNP test compared to that of echocardiograms and/or

hospitalization, as well as on the prevalence of HF in the population screened. Unfortunately, these parameters can vary considerably among departments, countries, and health-care systems; so that each laboratory/clinical department should analyze the cost-effectiveness in its own economical framework. Furthermore, cost-effectiveness analysis is also dependent on the sensitivity of BNP assay for detecting HF. Cost-effectiveness will improve if more specific assays are used: this would decrease the number of subjects with false-positive results, and consequently the number of further useless investigations. [Morimoto et al., 2004]

1.2.3 utility in prognosis

Several well-designed and conducted studies suggested that the NPs assay may be useful as a prognostic marker mainly in two clinical conditions: HF and acute coronary artery syndromes (ACS) [Clerico and Emdin, 2004].

In all these studies, NPs concentrations were always found to be independent risk markers for morbidity (increased future major cardiovascular events and/or hospitalization) and/or mortality in patients with acute or chronic HF. In some studies NPs levels were stronger predictors of mortality and/or major cardiovascular events than left ventricular EF, NYHA class, and/or presence of diabetes or hypertension, as well as sex and age in patients with chronic HF. [Clerico and Emdin, 2004]

On average, a systematic analysis of the most important studies suggested an odds ratio of about 2 for the risk of mortality in patients with BNP values above the cut-off [Clerico and Emdin, 2004].

Concentrations of BNP or NTproBNP have been shown to be strongly predictive of clinical outcomes in a wide range of populations including

patients at high risk for developing HF, asymptomatic patients with LV dysfunction, and symptomatic and/or advanced HF patients. Polled data from 19 HF studies including 5 studies with patients with asymptomatic LV dysfunction show that each 100 pg/mL increase in BNP was associated with a 35% increase in relative risk of death. [Doust et al., 2005]

In the Acute Decompensated Heart Failure National Registry (AD-HERE) database, in patients hospitalized for acute exacerbation of HFpEF or HFrEF, a single elevated BNP value correlated with increased in-hospital mortality; in addition, there was a direct relationship between quartiles of BNP concentration and mortality even after adjusting for multiple confounders including age, gender, vital signs, renal function, and sodium. [Fonarow et al., 2007]

NTproBNP values at the time of admission also strongly predict short- and long-term clinical outcomes. For example, [Januzzi et al., 2006a] in an analysis of the PRIDE trial examined 1-year outcomes of patients presenting to the ED with acute dyspnea and showed that the optimal NTproBNP cutoff point for 1-year mortality was 986 pg/mL (sensitivity=79% and specificity=68%, $P<.001$). In a multivariable model that included traditional risk factors for HF outcomes, NTproBNP greater than 986 pg/mL was the strongest predictor with a hazard ratio of 2.88. [Januzzi et al., 2006a]

A substudy of the A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure (Val-HeFT) trial also evaluated the prognostic value of BNP. This analysis was of 4300 patients who had serial serum BNP levels drawn at baseline, 4 months, and 12 months after enrollment. Patients with the largest percentage decline in BNP level from baseline during follow-up had the lowest morbidity and mortality. In contrast, patients with the highest percentage increase in BNP from baseline had the worst morbidity and mortality. BNP was the single strongest predictor of mortality among traditional risk factors; a single plasma BNP value ≥ 238 pg/mL predicted mor-

tality at 2 years better than a low BNP value less than 41 pg/mL (32.4 vs 9.7%). [Anand et al., 2003]

Similar findings are seen with NTproBNP. [Masson et al., 2006] showed that BNP and NTproBNP performed almost identically in predicting all-cause mortality in chronic HF (AUC was 0.665 for BNP vs 0.679 for NTproBNP, $P=0.07$). NTproBNP was superior to BNP for predicting mortality and morbidity ($P=0.03$) or hospitalization for HF ($P=0.01$). [Masson et al., 2006]

Several large, clinical trials have measured BNP or NTproBNP in patients presenting with ACS and either non-ST elevation MI or ST-elevation MI and consistently found that elevated NP values revealed important prognostic information. Both BNP and NTproBNP have been shown to be predictive of future adverse outcomes independent of other biomarkers, including the cardiac troponins. On a more detailed examination, it should be noted that elevated BNP or NTproBNP values typically predict future onset of HF or death, rather than ischemic events, whereas troponins typically predict recurrent ischemic events. [Gaggin and Januzzi, 2014]

The ValHeFT therapeutic trial (Valsartan Heart Failure Trial) in chronic HFrEF generated a large neurohormonal substudy providing data on the prognostic performance of both NTproBNP and BNP in chronic heart failure with reduced LVEF. After comprehensive adjustment for demographic, biochemical, clinical, and imaging predictors, NTproBNP remained an independent predictor of all-cause death and of readmission for HF. NTproBNP performed more strongly than endothelin, aldosterone, or norepinephrine. Median plasma NTproBNP concentrations of 895 pg/mL corresponded with an unadjusted crude annual mortality of approximately 10.1%. Increments of 500 pg/mL in NTproBNP conferred a 3.0% to 3.8% increment in risk of all-cause death or HF readmission. From first to tenth deciles of NTproBNP, the ValHeFT population exhibited a 10-fold increase in risk of all-cause death, HF readmission and the composite endpoint. [Latini et al.,


2004]

A large number of HF patients (n=4128) participated in the marker substudy from the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) in HFpEF. Plasma NTproBNP concentrations were related to outcomes, including all-cause death, cardiovascular admission, and HF deaths/HF admissions. A median NTproBNP of 339 pg/mL conferred a crude unadjusted annual mortality of 5.1%. In comprehensive multivariate modeling, NTproBNP was the strongest independent predictor of outcomes at 3 years of follow-up. Across septiles of NTproBNP, risk extended over 7- to 20-fold ranges from 8.1% to 59.9% for the primary endpoint, 2.7% to 36.5% for death and 2.1% to 38.9% for HF death/HF admission. NTproBNP, independent of multiple other accepted predictors, provided fine-grained prediction of clinical outcomes from low to very high risk. [Komajda et al., 2011]

In the PARADIGM trial comparing sacubitril/valsartan with enalapril in the treatment of HFrEF, plasma NTproBNP was measured in a subgroup (n=2080) of participants. Those with baseline levels of greater than 1000 pg/mL (n=1292) who achieved a decrease in NTproBNP to less than 1000 pg/mL at 1 month (24%) after randomization incurred 59% fewer deaths or admissions with HF compared with patients with NTproBNP remaining above this concentration. [Zile et al., 2016]

Risk calculators would likely be improved by incorporation of markers such as NTproBNP. [May et al., 2007] assessed the performance of the Seattle Heart Failure Model in ambulant chronic heart failure and found, in a subgroup of 544 out of 4077 registered patients with BNP results available, that the marker modestly augmented the c-statistic for prediction of the composite endpoint of survival free from death, transplantation, or LV assist device implantation from 0.73 to 0.78 for events at 1 year. [May et al., 2007]

[Berger et al., 2002] evaluated 452 ambulatory patients to determine whether serum BNP levels were predictive of future sudden cardiac



Number at risk

Did not achieve NT-proBNP <1000 pg/mL 903

Achieved NT-proBNP ≤1000 pg/mL 287

death (SCD) in patients with a left ventricular ejection fraction (LVEF) less than 35% within a 3-year follow-up period. Patients with a baseline serum BNP level greater than 130 pg/mL had higher rates of SCD, and the investigators suggested that patients with an increased BNP level at baseline should be evaluated for implantable cardiac defibrillator therapy. [Berger et al., 2002]

The 2004 Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT) trial evaluated 464 patients presenting to the ED with dyspnea and with NYHA class II to IV HF with baseline BNP greater than 100 pg/mL. The investigators found that baseline BNP levels greater than 200 pg/mL were strongly predictive of 90-day outcomes (combined HF visits, admissions, and mortality). [Maisel et al., 2004]

Failure of NP levels to decrease during an HF hospitalization while undergoing treatment is associated with worse prognosis and suggests a potential role for serial BNP measurement during HF hospitalization. [Cheng et al., 2001] evaluated 72 male veterans admitted with decompensated NYHA class III to IV HF and followed them for 30 days after discharge. Serial BNP levels were followed, starting with baseline values drawn within 24 hours of admission. Of these patients, 13 died and 9 were readmitted during the study period. Patients who died or were readmitted had increasing BNP levels during hospitalization. Patients who survived and were not readmitted showed decreasing BNP levels during admission. [Cheng et al., 2001]

In a study of 50 patients admitted for AHF, [Bettencourt et al., 2002] measured BNP levels at admission and then serially throughout hospitalization. Patients were followed for 6 months after discharge to determine whether BNP trends during the index hospitalization were predictive of end points including readmission for cardiovascular causes and death. Patients who died or were readmitted had less marked decline in BNP levels during hospitalization (770 ± 608 pg/mL to 643 ± 465 pg/mL; $P=0.08$), whereas increasing BNP levels during hospi-

talization were associated with increased event rate (hazard ratio=3.3; 95% confidence interval, 1.3–8.8).

In a study of the Get With the Guidelines Heart Failure Registry, 99,930 patients with AHF were stratified into subgroups based on gender and LVEF (reduced, < 40%; borderline, 40%–49%; preserved, ≥ 50%). Regardless of gender or LVEF, patients with BNP levels greater than the median had a higher mortality than those less than the median serum BNP level. [Hsieh et al.]

A substudy of the Framingham Offspring Study evaluated 3346 asymptomatic patients in the ambulatory setting and measured their serum BNP values over time. An increased BNP level greater than the 80th percentile was associated with an increased risk of death, first major cardiovascular event, atrial fibrillation (AF), stroke or transient ischemic attack, and HF. [Wang et al., 2004]

[Hartmann et al., 2004] in a substudy of the COPENHAGEN trial (n=1011) revealed that NTproBNP was consistently associated with an increased risk for all-cause mortality and hospitalisation for HF in patients with severe HF (LVEF ≤25%). [Gardner et al., 2003] studying 142 patients with advanced HF also reported that NTproBNP was an independent predictor of all cause mortality.

Several studies indicate that BNP and NTproBNP are powerful and independent risk markers of cardiovascular events (especially mortality) not only in patients with HF, but also in those with acute coronary syndrome . Some studies also suggested that the cardiovascular risk increases progressively to NPs concentration; that is, there is no threshold that actually identifies patients with null risk. [Wiviott et al., 2004]

Several studies reported that NPs assay (in particular BNP and NTproBNP) provides valuable prognostic information in patients with ACS. A meta-analysis confirmed the powerful prognostic value of BNP/NTproBNP in patients with ACS for death both in the short term (≤50 days, mean

odds ratio 3.38, CI 95% 2.44-4.68) and long term (>10 months, mean odds ratio 4.31, 3.77-4.94) [Galvani et al., 2004].

In a cohort of 236 patients with AMI a single measurement of plasma natriuretic peptide levels during the hospital admission provides limited prognostic information, while NTproBNP measured in the 30 days after AMI identifies a cohort of patients at increased risk of adverse outcome thereafter [Squire et al., 2005].

In patients with clinically stable, angiographically documented coronary artery disease, plasma NTproBNP levels are independently related to long term survival in a multivariate model. NTproBNP is a marker of long term mortality even in patients with stable coronary disease and add prognostic information above and beyond that provided by conventional cardiovascular risk factors and the degree of left ventricular systolic dysfunction [Kragelund et al., 2005].

In order to explain these clinical findings, it is important to note that experimental studies in animals reported that myocardial ischemia or even hypoxia per se could induce the synthesis/secretion of NPs (in particular BNP) from the intact heart in vivo as well as ventricular cells in culture. Furthermore, these experimental data are also in accordance with clinical studies indicating that transient myocardial ischemia in patients with stable coronary artery disease is associated with an immediate rise in circulating BNP levels, and that the magnitude of rise is proportional to the severity of ischemia [Sabatine et al., 2004].

1.2.4 utility in treatment

NP guided treatment

Shortly after studies reported that change in BNP or NTproBNP was

associated with a change in prognosis and that therapies for HF may lower NP concentrations, it was not long before investigators began to examine the role of NP-guided HF management. Conceptually, the use of either peptide to guide therapy is based on the concept that BNP and NTproBNP inform a broad array of pathophysiology and do so in a manner that augments clinical judgment. That therapies with salutary effects in HF (such as β -blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, as well as cardiac resynchronization therapy) all reduce NP concentrations 41 has given further enthusiasm to explore this strategy in depth. [Gaggin and Januzzi, 2013]

Several studies have evaluated the role of BNP or NTproBNP-guided HF management with mixed results. However, there was great heterogeneity in study designs (in particular, target biomarker concentrations, study population characteristics, and resulting biomarker changes with biomarker-guided care) and many of the studies were underpowered. When results from available randomized trials were pooled, a 20% to 30% mortality reduction with biomarker-guided HF management over standard HF care has been observed. [Porapakham et al., 2010]

The associations between plasma BNPs and prognosis has provided the rationale for a series of controlled trials of hormone-guided therapy in chronic HF. Although individual trials have variously yielded positive or neutral results, serial meta-analyses have consistently indicated benefit from guided therapy with greater than 20% reductions in total mortality and HF hospitalizations. Meta-analyses of trials of NTproBNP-guided therapy in chronic heart failure suggest improved outcomes and confirm achievement of NTproBNP of less than 1000 pg/mL confers a better prognosis. All trials of marker-guided therapy have consistently confirmed the strong association between achieved plasma B-type peptide levels and outcome regardless of allocated treatment strategy. In addition, BNP-guided treatment reduced all-cause mortality in patients less than 75 years old. BNP-guided treatment

reduced hospitalizations caused by HF and cardiovascular disorders in all patients regardless of age or LVEF. [Troughton et al., 2014]

[Troughton et al., 2000] conducted a study including 69 patients with impaired systolic function ($EF \leq 40\%$) and symptomatic HF (NYHA class II-IV). Half of the patients received therapy guided by plasma NTproBNP, therapy in the remaining patients was guided by clinical monitoring at the same frequency, but with the physician blinded to the NTproBNP result. During the follow-up (minimum 6 months, median 9.5 months), there were fewer total cardiovascular events (death, hospital admission, or HF decompensation) in the NTproBNP-guided group than in the clinical group (19 vs 54, $p = 0.02$) (target 1680 pg/ml). Changes in left ventricular function, quality of life, renal function, and adverse events were similar in both groups [Troughton et al., 2000]

[Kazanegra et al., 2001] measured serial serum BNP levels and pulmonary capillary wedge pressures using Swan-Ganz catheters in patients admitted to the hospital for an AHF exacerbation. Treatment-related decreases in pulmonary capillary wedge pressures corresponded with declining serum BNP levels, suggesting that BNP levels should decline with diuresis.

The Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure (STARS-BNP) trial published in 2007 evaluated the use of BNP-guided treatment strategies compared with standard clinical therapy in 220 patients with NYHA class II to III HF who were taking optimal medical management (angiotensin-converting enzyme [ACE] inhibitors, β -blockers, and diuretics). Patients were randomized to receive BNP-guided treatment with a goal BNP level of less than 100 pg/mL or treatment guided by clinical and symptomatic improvement. By 15-month follow-up, patients in the BNP-guided treatment arm had a significantly lower primary outcome of HF-related death or readmission (24% vs 52%; $P < .001$). [Jourdain et al., 2007]

The 2009 NTproBNP-Assisted Treatment To Lessen Serial Cardiac

Study or subgroup	Weight	Hazard ratio	
		IV, Random, 95% CI	Y
1.1.1 Individual data			
Christchurch pilot	0.9%	0.15 [0.02, 1.20]	2
TIME-CHF	24.4%	0.67 [0.45, 1.00]	2
Vienna	10.5%	1.00 [0.54, 1.85]	2
PRIMA	26.1%	0.78 [0.53, 1.15]	2
Signal-HF	3.4%	1.12 [0.38, 3.25]	2
BATTLESCARRED	13.1%	0.94 [0.54, 1.63]	2
STARBRITE	0.8%	0.33 [0.03, 3.18]	2
UPSTEP	15.3%	1.03 [0.62, 1.71]	2
Subtotal (95% CI)	94.4%	0.82 [0.67, 1.01]	
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 5.95$, $df = 7$ ($P = .55$); $I^2 = 0\%$			
Test for overall effect: $Z = 1.91$ ($P = .06$)			
1.1.2 Aggregate data			
STARS_BNP	4.0%	0.61 [0.23, 1.64]	2
Anguita et al.	1.6%	1.38 [0.28, 6.80]	2
Subtotal (95% CI)	5.6%	0.77 [0.33, 1.78]	
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 0.73$, $df = 1$ ($P = .39$); $I^2 = 0\%$			
Test for overall effect: $Z = 0.62$ ($P = .54$)			
Total (95% CI)	100.0%	0.82 [0.67, 1.00]	
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 6.71$, $df = 9$ ($P = .67$); $I^2 = 0\%$			
Test for overall effect: $Z = 2.00$ ($P = .05$)			
Test for subgroup differences: $\chi^2 = 0.02$, $df = 1$ ($P = .88$), $I^2 = 0\%$			

Readmissions and Death (BATTLESCARRED) trial found similar results using NTproBNP-guided clinical management. In this trial, 364 patients admitted for HF exacerbation were assigned to NTproBNP guided therapy, intensive clinical management (using aggressive up-titration of HF medications to optimal clinical trial doses), or usual care using symptom-guided management. At 1-year follow-up, mortality was significantly lower in the NTproBNP guided treatment arm versus usual care (9.1% vs 18.9%; $P=.03$). By 3-year follow-up, mortality was significantly lower in the NTproBNP guided group (15.5%) compared with the intensive clinical management group (30.9%; $P=0.048$) and usual care group (31.3%; $P=0.021$). [Lainchbury et al., 2009]

The 2009 Trial of Intensified versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) study also evaluated NTproBNP-guided therapy. This trial included 499 patients with chronic HF who were older than 60 years, NYHA class greater than II, hospitalized for HF within the last year, and had a baseline NTproBNP level greater than twice the upper limit of normal. These patients were followed for 18 months after initial admission, and the NTproBNP-guided therapy arm had higher rates of survival and lower rates of all-cause hospitalizations in patients aged 60 to 75 years but not in patients older than 75 years ($P<0.02$). [Pfisterer et al., 2009]

However, at matched echocardiographic alterations, patients in whom BNP levels drop in response to therapy have a reduced rate of major cardiac events or mortality, compared to untreated hypertensive patients, who could have similar echocardiographic abnormalities. This represents the rationale for using the NPs assay for therapy decision making and for monitoring HF patients [Clerico and Emdin, 2004] [Richards and Troughton, 2004] [Bettencourt, 2004].

NPs as therapeutic agents

Therapy with combined angiotensin 2 type1 receptor blockade and neprilysin inhibition (ARNI) has recently been shown to be superior

to treatment with angiotensin-converting enzyme inhibition in chronic heart failure, offering an approximate 20% improvement in all key important clinical endpoints. [McMurray et al.]

Neprilysin mediates cleavage of the biologically active carboxy-terminals of ANP, BNP, and C-type NP, and prolongation of the circulating and tissue half-lives of these powerful effectors is presumed to underlie a significant proportion of the benefit offered by ARNI. [Bayes-Genis et al., 2016]

Prescription of ARNI in chronic HF resulted in sustained elevations in plasma BNP, whereas NTproBNP (which is not cleaved by neprilysin) decreased, reflecting impaired metabolism of carboxy-terminal BNP and decreased cardiac release of NP, respectively. [Packer et al., 2015]

The 2014 Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF) trial compared the novel neprilysin-angiotensin inhibitor LCZ696, a combination of the salt form of valsartan combined with sacubitril (an inhibitor of neprilysin, a circulating neutral endopeptidase involved in the degradation of NPs), with the ACE inhibitor enalapril and showed a dramatic improvement in the primary outcome of mortality and HF hospitalization with LCZ696. [McMurray et al.]

Trials were conducted to evaluate the ability of anaritide infusion to reduce the need for dialysis in patients with acute tubular necrosis. The initial study with 53 patients suggested a positive outcome for patients receiving anaritide because they had increased creatinine clearance and a decreased need for dialysis [Rahman et al., 1994]. This led to the formation of a multicenter placebo-controlled clinical trial in 504 patients with acute tubular necrosis. While 24-h infusion of anaritide did not improve the overall survival of the patients without dialysis, it appeared that a subset of patients might have benefited [Allgren et al., 1997].

Another trial was conducted in patients with oliguric acute renal failure. However, this 222 patient trial indicated no statistically significant benefit of anaritide in dialysis-free survival. Both trials remarked on the severe hypotension that often occurred as a result of the anaritide infusion. In fact, it is this severe hypotension that appears to be limiting the utility of anaritide or nesiritide as a therapy for either heart failure or renal disease. The authors stated in their discussion, it is possible that if this hypotension could have been avoided, anaritide would have been efficacious [Lewis et al., 2000].

In 2004, studies conducted in Sweden compared the ability of the loop diuretic, furosemide, or mature ANP (1-28) to increase GFR, renal blood flow, and reduce renal oxygen consumption in patients with acute renal failure. They concluded that furosemide was a more effective agent [Sward et al., 2005].

[Mills et al., 1999] examined the effectiveness of 24-h infusion of nesiritide to patients with congestive heart failure in a multicenter, placebo-controlled trial. The peptide resulted in a reduction of both preload and afterload resulting in an increase in stroke volume and cardiac output.

The results of the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) study, compared the effects of the addition of nitroglycerin or nesiritide versus placebo to standard therapy. The group treated with nesiritide had improved dyspnea after 3 h treatment, while there was no difference in the other groups. The nitroglycerin group reported more adverse effects than the nesiritide group. Additionally, patients receiving nesiritide had less adverse cardiovascular effects at either the 0.015 or 0.03mcg/kg/min infusion rate compared to patients receiving dobutamine as determined by the 246-patient PRECEDENT Trial [deLissovoy et al., 2003].

The results of a 75-person study (BNP-CARDS study), however, suggest nesiritide has no detrimental effect on renal function, when cohorts

of similar baseline renal function were compared [Witteles et al., 2007].

Given that nesiritide was often reported to decrease pulmonary capillary wedge pressure, [Michaels et al., 2005] tested its effectiveness in pulmonary hypertension, however, they found no effect for a 30 min infusion.

However, at matched echocardiographic alterations, patients in whom BNP levels drop in response to therapy have a reduced rate of major cardiac events or mortality, compared to untreated hypertensive patients, who could have similar echocardiographic abnormalities. This represents the rationale for using the NPs assay for therapy decision making and for monitoring HF patients [Clerico and Emdin, 2004]

Medical therapy for HF is based on improving the symptoms and signs of fluid retention (change in dyspnea, edemas, and body weight are the usual markers of response to treatment) and titrating the dosage of drugs (such as diuretics, ACE inhibitors, β -blockers, and spironolactone) following the evidence from randomized clinical trials. There is no specific surrogate end-point for treating patients with HF that can be used to fine-tune therapy. The results of NPs assay (especially BNP/NTproBNP assay) may be useful in monitoring and tailoring the medical therapy in HF patients, and in providing a practical objective indicator of optimal therapy [Cowie and GF, 2002]

NPs usually respond to effective treatment with drugs or left ventricular assist device with a prompt reduction of their circulating levels. ACE inhibitors, valsartan, diuretics, nitrates, and endothelin receptor antagonists have been shown to reduce plasma NPs levels in parallel with hemodynamic and clinical improvement. More variable effects on plasma NPs levels have been reported after therapy with β -blockers. Some authors suggested that these variable effects may be at least in part attributable to different specificities or to ancillary properties of β -blockers [Latini et al., 2002].

It could be assumed that an acute administration of β -blockers causes an early rise in plasma NPs, while sustained treatment, significantly improving cardiac function and clinical conditions, induces a significant fall in hormone levels [Takeda et al., 2004].

A randomized clinical trial compared the titration of β -blocker therapy with bisoprolol according to plasma levels of BNP with empiric clinical therapy based on signs and symptoms. Forty-one patients with heart failure were randomized into a clinical trial. The clinical group had β -blocker dosage increased according to standard care, whereas the BNP group had β -blocker dosage up-titrated according to plasma BNP levels plus standard care. The primary outcome was mean β -blocker dose achieved after 3 months. BNP-guided up-titration of β -blocker in ambulatory patients with heart failure did not result significantly different doses of β -blocker at the end of 3 months. However, 45% of patients in the clinical group were on the maximum dose of β -blocker vs. only 19% of patients in the BNP group, although left ventricular ejection fraction was significantly improved in both groups by 7.3%. The slightly lower doses in the BNP group were possibly better tolerated than the doses achieved in the clinical group. Furthermore, a trend toward better quality of life was seen in the BNP group [da Silva et al., 2005].

1.2.5 limitations for clinical use

There are some important caveats to be cognizant of when interpreting BNP or NTproBNP results; both advanced age and male sex can lead to higher than expected BNP or NTproBNP values, for example, whereas other factors can lead to lower than expected results. Clinicians should have a good understanding of the broad factors that may influence both peptides either upwards or downwards.[Gaggin and Januzzi, 2014]

Elevation of plasma NTproBNP is not specific for ADHF. AF, renal failure, pulmonary embolism, and a number of other causes increase NTproBNP (Box 1). NTproBNP level should be considered in concert with the clinical history, examination findings, and data from other tests, including a standard laboratory workup and cardiac imaging. Age, obesity, preserved ejection fraction, renal dysfunction, and AF may affect the diagnostic performance of NTproBNP. Age is a strong determinant of NTproBNP. This relationship is independent of kidney and cardiac function, and the exact underlying mechanisms remain unclear. [Richards, 2018]

Many pulmonary disorders that result in elevated right ventricular pressures are also associated with elevated levels of these NPs: pulmonary embolism, pulmonary hypertension, congenital heart disease, and sleep apnea. In addition, most critical illnesses are associated with increased NP levels, although the exact mechanism is less clear: acute stroke, severe anemia, bacterial sepsis, severe burn, and acute respiratory distress syndrome. In most of these cases, the extent of BNP or NTproBNP elevation is not quite as high as the cutoff points used to diagnose ADHF, but clinical judgment is crucial in correctly interpreting NP concentrations in such patients. In addition, even in these "non-HF" causes of BNP or NTproBNP elevation, the prognostic value of the peptides hold. [Gaggin and Januzzi, 2014]

Renal dysfunction may cause increases in baseline serum NP levels, but the reason for this is not clearly understood. BNP is primarily cleared from circulation through degradation by circulating endogenous peptidases rather than by renal clearance. The mechanism behind this observation is probably multifactorial. [Maisel and Wettersten, 2018]

In addition, patients with renal dysfunction tend to have comorbid CV disorders that are associated with elevated BNP or NTproBNP values including LV hypertrophy and chronic volume overload state. In patients with renal dysfunction, a slightly higher BNP cutoff of 200 pg/mL or NTproBNP of 1200 pg/mL can be used with a good

accuracy. Alternatively, the age-stratified NTproBNP values, as used in patients without renal dysfunction, can be used as the cutoff with similar results. [Gaggin and Januzzi, 2014]

Estimated glomerular filtration fraction rate are inversely related to plasma concentrations of BNP and NTproBNP. For BNP, this has led to the recommendation that the BNP threshold be increased to 200 pg/mL for an estimated glomerular filtration rate of less than 60 mL/min/1.73 m. No specific corresponding change in cut-point is generally applied to NTproBNP values and the performance of age-specific NTproBNP diagnostic thresholds seem to be less affected. [DeFilippi et al., 2008]

On the other hand, certain states are associated with lower than expected BNP or NTproBNP concentrations. Patients with elevated body mass index (BMI) tend to have lower BNP or NTproBNP values compared with leaner counterparts. This occurrence is thought to be due to suppression of synthesis or release of NPs in obese patients.[Bayes-Genis et al., 2007]

Obesity lowers plasma NP concentrations through poorly understood mechanisms. Body mass index is actually inversely related to plasma NTproBNP concentrations in both health and HF. Unlike renal impairment or AF, which irretrievably impair the specificity and accuracy of plasma NTproBNP, obesity shifts the optimal threshold but preserves discriminatory performance. The effect on the diagnostic performance of BNP at 100 pg/mL is pronounced, with a clear loss of sensitivity that has led to the recommendation to reduce the cutpoint to 50 pg/mL for those with a BMI greater than of 30 kg/m². [Daniels et al., 2006]

Nevertheless, the diagnostic accuracy of NP cutoff points (age-stratified cutoff points for NTproBNP) used to diagnose ADHF remained acceptable regardless of BMI (AUC of 0.94 for lean, 0.95 for overweight, and 0.94 for obese patients), although BNP shows slightly lower sensitiv-

ity in those with high BMI and lower cut-offs have been advocated. [Bayes-Genis et al., 2007]

Higher baseline levels of BNP have been observed with increasing age; however, the exact mechanism is unknown. This age-related increase was independent of age-related diastolic dysfunction. Some investigators have hypothesized that this is caused by reduced expression of NPRs with age, which could result in decreased clearance of circulating BNPs in older patients. [Maisel and Wettersten, 2018]

Age-adjusted values enhance the specificity and accuracy of NTproBNP in diagnosis of ADHF at the cost of some loss of sensitivity. An NT-proBNP level of 450 pg/mL or more in the presence of new onset dyspnea is highly discriminating for ADHF (AUC, 0.99) in those less than 50 years of age. Most HF patients are older and the AUC falls progressively to 0.93 and then 0.86 in patients aged 50 to 75 years (optimal threshold of 900 pg/mL) and those older than 75 years (1800 pg/mL), respectively. Age-adjusted values have been calculated for NTproBNP but not BNP. [Januzzi et al., 2006b]

AF increases plasma NTproBNP whether HF is present or not. AF is a common complication of HF, and occurs in approximately 30% of populations with ADHF. AF reduces the discriminative performance NTproBNP for newly symptomatic ADHF, reducing the AUC on receiver operator analysis to approximately 0.7, which is well below the approximately 0.9 observed in HF cases with preserved sinus rhythm. The sensitivity of the standard thresholds of NTproBNP are preserved in the face of overall increases in plasma peptide concentrations, but specificity and accuracy are clearly reduced and cannot be improved solely by selection of an alternative cut point. Empirical observation indicates that between 65% and 85% of acutely breathless patients with AF and NTproBNP levels of greater than 300 pg/mL will receive a final diagnosis of acute HF and they should be managed as such until an alternative diagnosis is proven. [Richards et al., 2013]

Impact of renal disease on the acute decompensated heart failure patient presenting with dyspnea

	GFR (mL/min per 173 m ²)	Area Under the Curve
BNP	>90	0.91
	60–90	0.90
	30–59	0.81
	<30	0.86
NT-proBNP	≥60	0.95
	<60	0.88

Figure 13: CAPTION Abbreviations: BNP, B-type natriuretic peptide; GFR, glomerular filtration rate; NTproBNP, amino-terminal pro-B-type natriuretic peptide. [DeFilippi et al., 2008]

Several studies have shown that women have higher levels of BNP and NTproBNP. These studies evaluated age matched cohorts in which serum BNP and NTproBNP levels were higher in women than in men at any age, although the reason for this finding was not clear. Some have proposed that estrogen levels may play a role in this observation, because women on hormone replacement therapy had higher baseline serum BNP levels than those not taking hormone therapy. [Maisel and Wettersten, 2018]

Although obesity is a well-documented factor that can decrease baseline serum BNP level, the exact mechanism behind this remains unclear. Adipocytes are known to have increased concentration of NPRs, thus obese patients may have greater clearance of BNP by adipocytes. However, other studies have shown a correlation between BNP levels and lean mass rather than fat, which contradicts this hypothesis. It is less clear whether serum NTproBNP level is similarly decreased in obese patients, and, unlike BNP, NTproBNP is not cleared by NPRs (natriuretic peptide receptors). [Maisel and Wettersten, 2018]

As the clinical use of sacubitril-valsartan becomes more widespread, there is a growing concern that the measurement of serum NP levels in patients taking this drug may be problematic. In patients taking the neprilysin inhibitor, levels of BNP, which is broken down by neprilysin among other enzymes, may be increased because of decreased serum breakdown rather than because of change in underlying disease state (such as volume overload in AHF), potentially interfering with the prognostic and diagnostic utility of BNP. [McKie and Burnett, 2016]

In this setting the relationship of NTproBNP to intracardiac pressures and HF status, plasma is undistorted, whereas BNP is no longer a reliable marker. NTproBNP but not BNP remains a valid marker during ARNI therapy. Where ARNI therapy is contemplated or already in place, NTproBNP is the marker of choice in assessment of possible incident ADHF and for serial monitoring. [Richards, 2018]

Results from the PARADIGM-HF trial did show that plasma BNP concentrations were significantly increased in patients taking sacubitril-valsartan versus enalapril, whereas NTproBNP levels were significantly lower in the sacubitril-valsartan group. However, the decreases were only modest and, although significantly different between the two treatment arms, the mean serum values in each group decreased to well within the anticipated variation of these biomarkers. [Maisel and Wettersten, 2018]

Although more studies will be needed to determine the exact effect of neprilysin inhibition on BNP, there are some data to support that NTproBNP may be more reliable in patients taking sacubitril. The earlier Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction (PARAMOUNT) trial examined effects of sacubitril-valsartan compared with valsartan alone in patients with chronic HF with preserved ejection fraction. Although significant early declines in NTproBNP were observed at 12 weeks, NTproBNP levels were no longer significantly different between the two groups after 36 weeks. Serum BNP was not measured in this trial. [Maisel and Wettersten, 2018]

A large number of patients with only mild HF (NYHA classes I and II) may have values slightly above or even under the 99th percentile of distribution values of BNP concentration in healthy subjects. In these patients, successful treatment and consequent improvement in cardiac function and exercise capacity, and reduction in filling pressure and cardiac volumes, is usually associated with a marked fall in NPs levels: thus, a larger number of patients could have BNP values within the reference range values [Clerico and Emdin, 2004].

The variability of measured plasma concentrations of many substances is due to three different sources: pre-analytical, analytical and inherent biological variation. The latter is usually described as a random variation around a homeostatic setting point, and defined as the intra-individual or within-subject biological variation [Fraser, 2004].

In order to achieve a correct interpretation of serial test results that are collected for follow-up or tailored treatment of HF patients, several studies evaluated the biological variation of BNP and its related peptides, in both healthy subjects and cardiac patients. Due to secretory bursts and its rapid turnover (half-life about 15-20 min), intra-individual biological variations of plasma BNP levels were found to be very large, in both healthy subjects and patients with heart failure (ranging from 30 to 50%). According to this, only a decrease of more than 50% or a more than 2-fold increase in plasma BNP should be assumed to be statistically significant in an individual patient. [Wu et al., 2003a]

In contrast with this assumption, a clinical trial by [Takeda et al., 2004] has suggested that a BNP decrease inferior to this calculated reference change could be clinically relevant in patients with heart failure. In this study, only the group of patients treated with the β -blocker agent carvedilol, who respond on average with a decrease of only 38% in plasma BNP, showed a clinical improvement [Takeda et al., 2004].

Furthermore, several studies have demonstrated that cardiovascular risk (mortality or major cardiovascular events) increases continuously and progressively throughout the whole range of BNP concentrations in patients with cardiovascular diseases [Clerico and Emdin, 2004].

In order to explain these conflicting findings, it should be taken into account that BNP secretion is closely regulated by specific pathophysiological mechanisms. Accordingly the clinician should consider all changes in BNP concentration as potentially clinically relevant, even when narrower than the calculated intra-individual biological variation. In other words, BNP variations should be interpreted and considered by physicians, as the variability of heart rhythm and blood pressure, by taking into account clinical history and examination, comprehensive of the response to specific treatments, as well as of laboratory and instrumental test findings. [Clerico et al., 2005].

References

- Ahluwalia and Hobbs AJ. Endothelium-derived c-type natriuretic peptide more than just a hyperpolarized factor. *Trends Pharmacol Sci*, 26:162–167, 2005.
- Ahluwalia, MacAllister RJ, and Hobbs AJ. Vascular actions of natriuretic peptides. cyclic gmp-dependent and -independent mechanisms. *Basic Res Cardiol*, 99:83–89, 2004.
- RL Allgren, TC Marbury, SN Rahman, LS Weisberg, AZ Fenves, RA Lafayette, RM Sweet, FC Genter, BR Kurnik, JD Conger, and MH Sayegh. Anaritide in acute tubular necrosis; auriculin anaritide acute renal failure study group. *N Engl J Med*, 336:828–834, 1997.
- Anand, Fisher, Chiang, and et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (val-heft). *Circulation*, 107:1278–83, 2003.
- Andreassi, Del Ry S, and Palmieri C et al. Up-regulation of ‘clearance’ receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. *Eur J Heart Fail*, 3:407–414, 2001.
- CF Bartels, H Bukulmez, P Padayatti, DK Rhee, C van Ravenswaaij-Arts, RM Pauli, S Mundlos, D Chitayat, LY Shih, LI Al-Gazali, S Kant, T Cole, J Morton, V Cormier-Daire, L Faivre, M Lees, J Kirk, GR Mortier, J Leroy, B Zabel, CA Kim, Y Crow, NE Braverman, F van-den Akker, and MLA Warman. Mutations in the transmembrane natriuretic peptide receptor npr-b impair skeletal growth and cause acromesomelic dysplasia, type maroteaux. *Am J Hum Genet*, 75:27–34, 2004.
- Baruch, Glazer RD, and Aknay N et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in

- the valsartan heart failure trial (valheft). *Am Heart J*, 148:951–957, 2004.
- Bayes-Genis, Lloyd-Jones, van Kimmenade, and et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. *Arch Intern Med*, 167:400–7, 2007.
- Bayes-Genis, Barallat, and Richards. A test in context. neprilysin: function, inhibition and biomarker. *J Am Coll Cardiol*, 68:639–53, 2016.
- Belenky, Smith, and Zhang. The effect of class-specific protease inhibitors on the stabilization of b-type natriuretic peptide in human plasma. *Clin Chim Acta*, 340:163–172, 2004.
- R Berger, M Huelsman, K Strecker, A Bojic, P Moser, B Stanek, and R Pacher. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. *Circulation*, 105:2392–7, 2002.
- Bettencourt. Nt-probnp and bnp: biomarkers for heart failure management. (Review) *Eur J Heart Fail*, 6:359–363, 2004.
- Bettencourt, Ferreira, Azevedo, and et al. Preliminary data on the potential usefulness of b-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. *Am J Med*, 113, 2002.
- Booz. Putting the brakes on cardiac hypertrophy exploiting the no-cgmp counter-regulatory system. *Hypertension*, 45:341–346, 2005.
- S Bruins, MR Fokkema, JW Romer, MJ Dejongste, FP van der Dijs, JM van den Ouweland, and FA Muskiet. High intraindividual variation of b-type natriuretic peptide (bnp) and amino-terminal probnp in patients with stable chronic heart failure. *Clin Chem*, 50:2052–8, 2004.

- CJ Charles, TC Prickett, EA Espiner, MT Rademaker, AM Richards, and TG Yandle. Regional sampling and the effects of experimental heart failure in sheep: differential responses in a, b and c-type natriuretic peptides. *Peptides*, 27:62–68, 2006.
- Charloux, Piquard F, and Doutreleau S et al. Mechanisms of renal hyposensitiveness to anp in heart failure. (Review) *Eur J Clin Invest*, 33:769–778, 2003.
- Cheng, Kazanagra, Garcia, and et al. A rapid bedside test for b-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. *J Am Coll Cardiol*, 37: 386–91, 2001.
- Clerico and Emdin. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. (Review) *Clin Chem*, 50:33–50, 2004.
- Clerico, Iervasi G, and Pilo A. Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. *Curr Drug Metab*, 1:85–105, 2000.
- Clerico, Del Ry S, and Maffei S et al. Circulating levels of cardiac natriuretic hormones in healthy adult subjects: effects of aging and sex. *Clin Chem Lab Med*, 40:371–377, 2002.
- Clerico, Zucchelli GC, Pilo A, and Emdin M. Clinical relevance of biological variation of b-type natriuretic peptide. (Letter) *Clin Chem*, 51:925–926, 2005.
- Cowie and Mendez GF. Bnp and congestive heart failure. (Review) *Prog Cardiovasc Dis*, 44:293–321, 2002.
- MR Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, and G Francis. Clinical applications of b-type natriuretic peptide (bnp) testing. *Eur Heart J*, 24:1710–8, 2003.

- Beck da Silva, de Bold A, and Fraser M et al. Bnp-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. *Congest Heart Fail*, 11:248–253, 2005.
- Daniels, Clopton, and Bhalla et al. How obesity affects the cut-points for b-type natriuretic peptide in the diagnosis of acute heart failure. results from the breathing not properly multinational study. *Am Heart J*, 151:999–1005, 2006.
- LB Daniels and AS Maisel. natriuretics peptides. *Journal of American College of Cardiology*, 50:2357–68, 2007.
- DeFilippi, van Kimmenade, and Pinto. Amino-terminal pro-b-type natriuretic peptide testing in renal disease. *Am J Cardiol*, 101:82–8, 2008.
- G deLissovoy, DM Stier, G Ciesla, M Munger, and AJ Burger. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. *Am J Cardiol*, 92:631–633, 2003.
- DM Dickey, DR Flora, PM Bryan, X Xu, Y Chen, and LR Potter. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (npr)-b, not npr-a, is the predominant natriuretic peptide receptor in the failing heart. *Endocrinology*, 148:35183522, 2007.
- Doust, Glasziou PP, Pietrzak E, and Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. (Review) *Arch Intern Med*, 164:1978–1984, 2004.
- Doust, Pietrzak E, Dobson A, and Glasziou P. How well does b-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. (Review) *BMJ*, 330:625–633, 2005.
- Emdin, Passino C, and Prontera C et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects

- and patients with heart failure. *Clin Chem Lab Med*, 42:627–636, 2004.
- Evans, Youssef, and Yandle TG. Effects of endothelin-1 on release of adrenomedullin and c-type natriuretic peptide from individual human vascular endothelial cells. *J Endocrinol*, 175:225–232, 2002.
- Fan, Bryan PM, and Antos LK et al. Downregulation does not mediate natriuretic peptide dependent desensitization of npr-a or npr-b: guanylyl cyclase-linked natriuretic peptide receptors do not internalize. *Mol Pharmacol (printed online Sept 30, 2004)*, 2004.
- Fan, Bryan, and Antos LK. Down-regulation does not mediate natriuretic peptide-dependent desensitization of natriuretic peptide receptor (npr)-a or npr-b. guanylyl cyclase-linked natriuretic peptide receptors do not internalize. *Mol Pharmacol*, 67:1–10, 2005a.
- D Fan, PM Bryan, LK Antos, RJ Potthast, and LR Potter. Down-regulation does not mediate natriuretic peptide-dependent desensitization of natriuretic peptide receptor (npr)-a or npr-b: Guanylyl cyclase-linked natriuretic peptide receptors do not internalize. *Mol Pharmacol*, 67:174183, 2005b.
- Fonarow, Peacock, Phillips, et al, ADHERE Scientific Advisory Committee, and Investigators. Admission b-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. *J Am Coll Cardiol*, 49:1943–50, 2007.
- Foote, Pearlman JD, and Siegel AH and Yeo KT. Detection of exercise-induced ischemia by changes in b-type natriuretic peptide. *J Am Coll Cardiol*, 44:1980–1987, 2004.
- Fraser. Inherent biological variation and reference values. (*Review*) *Clin Chem Lab Med*, 42:758–764, 2004.
- Gaggin and Januzzi. Biomarkers and diagnostics in heart failure. *Biochim Biophys Acta*, 1832(12):2442–50, 2013.

- Hanna K Gaggin and James L Januzzi. Natriuretic peptides in heart failure syndrome. *Clin Lab Med*, 34:43–58, 2014.
- Galvani, Ferrini D, and Ottani T. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. (Review) *Eur J Heart Fail*, 6:327–333, 2004.
- RS Gardner, F Ozalp, AJ Murday, SD Robb, and TA McDonagh. N-terminal pro-brain natriuretic peptide a new gold standard in predicting mortality in patients with advanced heart failure. *Eur Heart J*, 24:1735–43, 2003.
- Gharib and Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. (Review) *Eur J Heart Fail*, 4:235–242, 2002.
- Giannessi, Andreassi MG, and Del Ry S et al. Possibility of age regulation of the natriuretic peptide c-receptor in human platelets. *J Endocrinol Invest*, 24:8–16, 2001.
- Goetze. Biochemistry of pro-b-type natriuretic peptide-derived peptides the endocrine heart revisited. *Clin Chem*, 9:1503–1510, 2004a.
- Goetze. Biochemistry of pro-b-type natriuretic peptide-derived peptides: the endocrine heart revisited. (Review) *Clin Chem*, 9:1503–1510, 2004b.
- Gyurko, Kuhlencordt, Fishman, and Huang OL. Modulation of mouse cardiac function in vivo by enos and anp. *Am J Physiol*, 278:H971–981, 2000.
- C Hall. Nt-probnp: the mechanism behind the marker. *J Card Fail*, 11:S81–3, 2005.
- Han and Hasin. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. *Cardiovasc Drugs Ther*, 17:41–52, 2003.

- F Hartmann, M Packer, AJ Coats, MB Fowler, H Krum, P Mohacsi, JL Rouleau, M Tendera, A Castaigne, SD Anker, I Amann-Zalan, S Hoersch, and HA Katus. Prognostic impact of plasma n-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (copernicus) trial. *Circulation*, 110:1780–6, 2004.
- Hedberg, Lonnberg I, and Jonason T et al. Electrocardiogram and b-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. *Am Heart J*, 148:524–529, 2004.
- Heidenreich, Gubens MA, and Fonarow GC et al. Cost-effectiveness of screening with b-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. *J Am Coll Cardiol*, 43: 1019–1026, 2004.
- R Holtwick, M Gotthardt, B Skryabin, M Steinmetz, R Potthast, B Zetsche, RE Hammer, J Herz, and M Kuhn. Smooth muscle-selective deletion of guanylyl cyclase-a prevents the acute but not chronic effects of anp on blood pressure. *Proc Natl Acad Sci U S A*, 99:7142–7147, 2002.
- Houben, van der Zander, and de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man physiology and pharmacology. *Fundam Clin Pharmacol*, 19:411–419, 2005.
- Hsich, Grau-Sepulveda, Hernandez, and et al. Relationship between sex, ejection fraction, and b-type natriuretic peptide levels in patients hospitalized with heart failure and associations with in-hospital outcomes: findings from the get with the guideline-heart failure registry.
- Hutcheon, Gillespie ND, Struthers AD, and McMurdo ME. B-type natriuretic peptide in the diagnosis of elderly day hospital patients. *Age Ageing*, 31:295–301, 2002.

- Y Iwanaga, I Nishi, S Furuichi, T Noguchi, K Sase, and Y Kihara. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. *Journal of American College of Cardiology*, 47:742–8, 2006.
- Januzzi, Sakhuja, O'Donoghue, and et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. *Arch Intern Med*, 166:315–20, 2006a.
- Januzzi, van Kimmenade, Lainchbury, Bayes-Genis, Ordonez-Llanos, Santalo-Bel, Pinto, and Richards. Nt-probnp testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of nt-probnp (icon) study. *Eur Heart J*, 27:330–7, 2006b.
- Jr Januzzi, CA Camargo, S Anwaruddin, AL Baggish, AA Chen, DG Krauser, R Tung, R Cameron, JT Nagurney, CU Chae, DM Lloyd-Jones, DF Brown, S Foran-Melanson, PM Sluss, E Lee-Lewandrowski, and KB Lewandrowski. The n-terminal pro-bnp investigation of dyspnea in the emergency department (pride) study. *Am J Cardiol*, 95:948–54, 2005.
- Joubert, Labrecque, and De Lean. Reduced activity of the npr-a kinase triggers dephosphorylation and homologous desensitization of the receptor. *Biochemistry*, 40:11096–11105, 2001.
- Jourdain, Jondeau, and Funck et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the stars-bnp multicenter study. *J Am Coll Cardiol*, 49, 2007.
- R Kazanegra, V Cheng, and A Garcia et al. A rapid test for b-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. *J Card Fail*, 7:21–9, 2001.

- JW Knowles, G Esposito, L Mao, JR Hagaman, JE Fox, O Smithies, HA Rockman, and N Maeda. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor adeficient mice. *J Clin Invest*, 107:975–984, 2001.
- Komajda, Carson, and Hetzel et al. Factors associated with outcome in heart failure with preserved ejection fraction findings from the irbesartan in heart failure with preserved ejection fraction study (i-preserve). *Circ Heart Fail*, 4:27–35, 2011.
- Kragelund, Gronning B, and Kober L et al. N-terminal pro-b-type natriuretic peptide and long-term mortality in stable coronary heart disease. *N Engl J Med*, 352:666–675, 2005.
- Kraigher-Krainer, Shah, and Gupta et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. *J Am Coll Cardiol*, 63:447–56, 2014.
- Kuhn, Voss M, and Mitko D et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. *Cardiovasc Res*, 64:308–314, 2004.
- JG Lainchbury, RW Troughton, and KM Strangman et al. N-terminal pro-b-type natriuretic peptide-guided treatment for chronic heart failure: results from the battlescarred (nt-probnp-assisted treatment to lessen serial cardiac readmissions and death) trial. *J Am Coll Cardiol*, 55:53–60, 2009.
- TH Langenickel, J Buttgereit, I Pagel-Langenickel, M Lindner, J Monti, K Beuerlein, N Al-Saadi, R Plehm, E Popova, J Tank, R Dietz, R Willenbrock, and M Bader. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor b. *Proc Natl Acad Sci U S A*, 103:4735–4740, 2006.

- Latini, Masson S, De Angelis N, and Anand I. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. (*Review*) *J Card Fail*, 8:288–299, 2002.
- Latini, Masson, and Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in val-heft. *Eur Heart J*, 25:292–299, 2004.
- J Lewis, MM Salem, GM Chertow, LS Weisberg, F McGrew, TC Marbury, and RL Allgren. Atrial natriuretic factor in oliguric acute renal failure; anaritide acute renal failure study group. *Am J Kidney Dis*, 36:767–774, 2000.
- Maisel, Hollander, Guss, and Rapid Emergency Department Heart Failure Outpatient Trial Investigators. et al. Primary results of the rapid emergency department heart failure outpatient trial (redhot). a multicenter study of b-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. *J Am Coll Cardiol*, 44:1328–33, 2004.
- Alan S Maisel and Nicholas Wettersten. Natriuretic peptides in heart failure. atrial and b-type natriuretic peptides. *Heart Failure Clin*, 14:13–25, 2018.
- AS Maisel, P Krishnaswamy, RM Nowak, J McCord, JE Hollander, P Duc, T Omland, AB Storrow, WT Abraham, AH Wu, P Clifton, PG Steg, A Westheim, CW Knudsen, A Perez, R Kazanegra, HC Herrmann, and Investigators of Breathing Not Properly Multi-national Study. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*, 347:161–7, 2002.
- AS Maisel, J McCord, RM Nowak, JE Hollander, AH Wu, P Duc, T Omland, AB Storrow, P Krishnaswamy, WT Abraham, P Clifton, G Steg, MC Aumont, A Westheim, CW Knudsen, A Perez, R Kamin, R Kazanegra, HC Herrmann, and PA McCullough. Bed-side b-type natriuretic peptide in the emergency diagnosis of heart

- failure with reduced or preserved ejection fraction: Results from the breathing not properly multinational study. *J Am Coll Cardiol*, 41: 2010–7, 2003.
- S Masson, R Latini, IS Anand, T Vago, L Angelici, S Barlera, ED Missov, A Clerico, G Tognoni, and JN Cohn (on behalf of the Val-HeFT Investigators). Direct comparison of b-type natriuretic peptide (bnp) and amino-terminal probnp in a larger population of patients with chronic and symptomatic heart failure: the valsartan heart failure data. *Clin Chem*, 52:1528–1538, 2006.
- May, Horne, Levy, and et al. Validation of the seattle heart failure model in a community-based heart failure population and enhancement by adding b-type natriuretic peptide. *Am J Cardiol*, 100:697–700, 2007.
- PM McKie and JC Burnett. Nt-probnp: the gold standard biomarker in heart failure. *J Am Coll Cardiol*, 68:2437–9, 2016.
- JJ McMurray, M Packer, and AS Desai.
- AD Michaels, K Chatterjee, and T De-Marco. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. *J Card Fail*, 11:425–431, 2005.
- RM Mills, TH LeJemtel, DP Horton, C Liang, R Lang, MA Silver, C Lui, and K Chatterjee. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial; natrekor study group. *J Am Coll Cardiol*, 34:155–162, 1999.
- GW Moe, J Howlett, Januzzi et al, and Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-b-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the canadian prospec-

- tive randomized multicenter improve-chf study. *Circulation*, 115: 3103–10, 2007.
- Morimoto, Hayashino Y, and Shimbo T et al. Is b-type natriuretic peptide-guided heart failure management cost-effective? *Int J Cardiol*, 96:177–181, 2004.
- Morita, Yasue, and Yoshimura et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. *Circulation*, 88:82–91, 1993.
- C Mueller, A Scholer, and K Laule-Kilian et al. Use of b-type natriuretic peptide in the evaluation and management of acute dyspnea. *N Engl J Med*, 350:647–54, 2004.
- Nakamura, Sakai T, and Osawa M et al. Comparison of positive cases for b-type natriuretic peptide and ecg testing for identification of precursor forms of heart failure in an elderly population. *Int Heart J*, 46:477–487, 2005.
- Nakanishi, Saito, and Kishimoto. Role of natriuretic peptide receptor guanylyl cyclase-a in myocardial infarction evaluated using genetically engineered mice. *Hypertension*, 46:1–7, 2005.
- Nakayama. The genetic contribution of the natriuretic peptide system to cardiovascular diseases. *Endocr J*, 52:11–21, 2005.
- Ng, Loke I, and Davies JE et al. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. *Eur J Heart Fail*, 5:775–782, 2003.
- Ng, Geeranavor, Jennings, Loki, and O’Brien. Diagnosis of heart failure using urinary natriuretic peptides. *Clin Sci*, 106:129–133, 2004.
- Nielsen, McDonagh TA, Robb SD, and Dargie HJ. Retrospective analysis of the costeffectiveness of using plasma brain natriuretic peptide

- in screening for left ventricular systolic dysfunction in the general population. *J Am Coll Cardiol*, 41:113–120, 2003.
- Ogawa, Qiu, Ogata, and Risono KS. Crystal structure of hormone-bound atrial natriuretic peptide receptor extracellular domain rotation mechanism for transmembrane signal transduction. *J Biol Chem*, 279:28625–28631, 2004.
- RC Olney, H Bukulmez, CF Bartels, TC Prickett, EA Espiner, LR Potter, and ML Warman. Heterozygous mutations in natriuretic peptide receptor-b (npr2) are associated with short stature. *J Clin Endocrinol Metab*, 91:1229–1232, 2006.
- Packer, McMurray, PARADIGM-HF Investigators Desai et al, and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation*, 131:54–61, 2015.
- Pandey. Biology of natriuretic peptides and their receptors. *Peptides*, 26:901–932, 2005.
- KN Pandey. Intracellular trafficking and metabolic turnover of ligand-bound guanylyl cyclase/atrial natriuretic peptide receptor-a into subcellular compartments. *Mol Cell Biochem*, 230:6172, 2002.
- K Pankow, Y Wang, F Gembardt, E Krause, X Sun, G Krause, HP Schultheiss, WE Siems, and T Walther. Successive action of meprin a and neprilysin catabolizes b-type natriuretic peptide. *Circ Res*, 101:875–882, 2007.
- Panteghini and Clerico. Understanding the clinical biochemistry of n-terminal pro-b-type natriuretic peptide: the prerequisite for its optimal clinical use. (Review) *Clin Lab*, 50:325–331, 2004.
- Panteghini, Cuccia C, and Bonetti G et al. Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. *Clin Chem Lab Med*, 41:164–168, 2003.

- JB Patel, ML Valencik, AM Pritchett, JC Burnett, JA McDonald, and MM Redfield. Cardiac-specific attenuation of natriuretic peptide a receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. *Am J Physiol Heart Circ Physiol*, 289:H777H784, 2005.
- Perras, Schultes, and Behn. Intranasal atrial natriuretic peptide acts as central nervous inhibitor of the hypothalamo-pituitary-adrenal stress system in humans. *J Clin Endocrinol Metab*, 89:4642–4648, 2004.
- M Pfisterer, P Buser, and H Rickli et al. Bnp-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (time-chf) randomized trial. *JAMA*, 301:383–92, 2009.
- Porapakham, Zimmet, Billah, and et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. *Arch Intern Med*, 170: 507–14, 2010.
- LR Potter. natriuretic peptide metabolism, clearance and degradation. *FEBS J*, 278:1808–17, 2011.
- R Potthast, SE Abbey-Hosch, LK Antos, JS Marchant, M Kuhn, and LR Potter. Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-b/guanylyl cyclase-b. *J Biol Chem*, 279: 48513–48519, 2004.
- Qian, Haruno, and Asada. Local expression of c-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. *Circ Res*, 91: 1063–1069, 2002.
- SN Rahman, GE Kim, AS Mathew, CA Goldberg, R Allgren,

- RW Schrier, and JD Conger. Effects of atrial natriuretic peptide in clinical acute renal failure. *Kidney Int*, 45:1731–1738, 1994.
- Ray, Arthaud M, and Lefort Y et al. Usefulness of b-type natriuretic peptide in elderly patients with acute dyspnea. *Intensive Care Med*, 30:2230–2236, 2004.
- Richards and Troughton. Nt-probnp in heart failure: therapy decisions and monitoring. (Review) *Eur J Heart Fail*, 6:351–354, 2004.
- Richards, Di Somma, and Mueller et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the biomarkers in acute heart failure (bach) study. *JACC Heart Fail*, 1:192–9, 2013.
- Arthur Mark Richards. N-terminal b-type natriuretic peptide in heart failure. *Heart Failure Clin*, 14:27–39, 2018.
- RA Rose and WR Giles. Natriuretic peptide c receptor signalling in the heart and vasculature. *J Physiol*, 586:353–366, 2008.
- Sabatine, Morrow DA, and de Lemos JA et al. TIMI Study Group. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. *J Am Coll Cardiol*, 44:1988–1995, 2004.
- K Sabrane, MN Kruse, L Fabritz, B Zetsche, D Mitko, BV Skryabin, M Zwiener, HA Baba, M Yanagisawa, and M Kuhn. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. *J Clin Invest*, 115:1666–1674, 2005.
- Sandri, Salvatici M, and Cardinale D et al. N-terminal pro-b-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? *Clin Chem*, 51:1405–1410, 2005.
- Sarzani, Strazzullo P, and Salvi F et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. *Obes Res*, 12:351–356, 2004.

- Squire, Orn S, and Ng LL et al. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an optimal substudy. *J Card Fail*, 11:492–497, 2005.
- Toru Suzuki, Tsutomu Yamazaki, and Yoshio Yazaki. The role of natriuretic peptides in the cardiovascular system. *Cardiovascular Research*, 51:489–494, 2001.
- K Sward, F Valsson, J Sellgren, and SE Ricksten. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. *Intensive Care Med*, 31:79–85, 2005.
- Takeda, Fukutomi, and Suzuki et al. Effects of carvedilol on plasma b-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. *Am J Cardiol*, 94: 448–453, 2004.
- N Tamura, Y Ogawa, H Chusho, K Nakamura, K Nakao, M Suda, M Kasahara, R Hashimoto, G Katsuura, M Mukoyama, H Itoh, Y Saito, I Tanaka, H Otani, and M Katsuki. Cardiac fibrosis in mice lacking brain natriuretic peptide. *Proc Natl Acad Sci U S A*, 97:4239–4244, 2000.
- Troughton and Richards. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. *JACC Cardio-vasc Imaging*, 2:216–25, 2009.
- RW Troughton, CM Frampton, TG Yandle, EA Espiner, MG Nicholls, and AM Richards. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (n-bnp) concentrations. *Lancet*, 355:1126–30, 2000.
- RW Troughton, CM Frampton, and HP Brunner-La Rocca et al. Effect of b-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. *Eur Heart J*, 35:1559–67, 2014.

- Quynh Troung, James Bayley, Udo Hoffman, Fabian Bamberg, Christopher Schlett, John Nagurney, Wolfgang Koenig, and James Januzzi. Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-t for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the romicat trial. *Am Heart J*, 163(6):972–9, 2012.
- T Tsuji and T Kunieda. A loss-of-function mutation in natriuretic peptide receptor 2 (npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse. *J Biol Chem*, 280:14288–14292, 2005.
- Ueda, Yokouchi M, and Suzuki T et al. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. *Am J Med*, 114:266–270, 2003.
- Valle, Aspromonte N, and Barro S et al. The nt-probnp assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. *Eur J Heart Fail*, 7:542–551, 2005.
- Vasan, Benjamin, and Larson et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. *JAMA*, 288:1252–1259, 2002.
- Vesely. Natriuretic peptides and acute renal failure. *Am J Physiol Renal Physiol*, 285:F167–177, 2003.
- MA Vieira, M Gao, LN Nikonova, and T Maack. Molecular and cellular physiology of the dissociation of atrial natriuretic peptide from guanylyl cyclase a receptors. *J Biol Chem*, 276:36438–36445, 2001.
- Vollmar. The role of atrial natriuretic peptide in the immune system. *Peptides*, 26:1086–1094, 2005.
- Vollmar and Kiemer AK. Immunomodulatory and cytoprotective function of atrial natriuretic peptide. *Crit Rev Immunol*, 21:473–485, 2001.

- M Volpe, M Carnovali, and V Mastromarino. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. *Clin Sci*, 130:57–77, 2016.
- Walther, Klostermann, and Hering-Walther. Fibrosis rather than blood pressure determines cardiac bnp expression in mice. *Regul Pept*, 116:95–100, 2003.
- Wang, Larson, Levy, and et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*, 350, 2004.
- Y Wang, MC deWaard, A Sterner-Kock, H Stepan, HP Schultheiss, DJ Duncker, and T Walther. Cardiomyocyte-restricted over-expression of c-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. *Eur J Heart Fail*, 9: 548–557, 2007.
- Waschek. Developmental actions of natriuretic peptides in the brain and skeleton. *Cell Mol Life Sci*, 61:2332–2342, 2004.
- Williams, Ng, and O’Brien et al. Comparison of plasma n-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. *Am J Cardiol*, 93: 1560–1561, 2004.
- RM Witteles, D Kao, D Christopherson, K Matsuda, RH Vagelos, D Schreiber, and MB Fowler. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. *J Am Coll Cardiol*, 50:1835–1840, 2007.
- Wiviott, de Lemos JA, and Morrow DA. Pathophysiology, prognostic significance and clinical utility of b-type natriuretic peptide in acute coronary syndromes. (Review) *Clin Chim Acta*, 346:119–128, 2004.

- Woodard, Rosado, and Brown. Expression and control of c-type natriuretic peptide in rat vascular smooth muscle cells. *Am J Physiol Reg Int Comp Physiol*, 282:R156–165, 2002.
- Wright, Doughty, and Pearl et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. *J Am Coll Cardiol*, 42:1793–1800, 2003.
- Wu, Smith A, and Wieczorek S et al. Biological variation for n-terminal proand btype natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. *Am J Cardiol*, 92:628–631, 2003a.
- C Wu, F Wu, J Pan, J Morser, and Q Wu. Furin-mediated processing of pro-c-type natriuretic peptide. *J Biol Chem*, 278:25847–25852, 2003b.
- A Yasoda, Y Komatsu, H Chusho, T Miyazawa, A Ozasa, M Miura, T Kurihara, T Rogi, S Tanaka, M Suda, N Tamura, Y Ogawa, and K Nakao. Overexpression of *cnip* in chondrocytes rescues achondroplasia through a mapk-dependent pathway. *Nat Med*, 10:80–86, 2004.
- Zile, Claggert, Prescott, and et al. Prognostic implications of changes in n-terminal pro-b-type natriuretic peptide in patients with heart failure. *J Am Coll Cardiol*, 68:2425–36, 2016.